---
document_datetime: 2026-01-16 16:15:46
document_pages: 60
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/ervebo-vr-0000280470-epar-assessment-report-variation_en.pdf
document_name: ervebo-vr-0000280470-epar-assessment-report-variation_en.pdf
version: success
processing_time: 128.461213
conversion_datetime: 2026-01-17 12:59:08.439165
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

EMADOC-1700519818-2258789 Committee for Medicinal Products for Human Use (CHMP)

## Type II group of variations assessment report

Procedure No. EMA/VR/0000280470

Invented name: Ervebo

Common name: RECOMBINANT VESICULAR STOMATITIS VIRUS (STRAIN INDIANA) WITH A DELETION OF THE ENVELOPE GLYCOPROTEIN, REPLACED WITH THE ZAIRE EBOLAVIRUS (STRAIN KIKWIT-1995) SURFACE GLYCOPROTEIN

Marketing authorisation holder (MAH): Merck Sharp &amp; Dohme B.V.

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Current step                                               | Description                                                | Planned date                                               | Actual Date                                                |
|                                                            | Submission deadline                                        | 20 Jun 2025                                                | 19 Jun 2025                                                |
|                                                            | Validation                                                 | 7 Jul 2025                                                 | 2 Jul 2025                                                 |
|                                                            | Start date                                                 | 8 Jul 2025                                                 | 8 Jul 2025                                                 |
|                                                            | CHMP Rapporteur AR                                         | 11 Aug 2025                                                | 8 Aug 2025                                                 |
|                                                            | PRAC Rapporteur AR                                         | 18 Aug 2025                                                | 11 Aug 2025                                                |
|                                                            | PRAC comments                                              | 22 Aug 2025                                                | 22 Aug 2025                                                |
|                                                            | CHMP comments                                              | 25 Aug 2025                                                | 25 Aug 2025                                                |
|                                                            | Updated PRAC Rapporteur AR                                 | 26 Aug 2025                                                | 25 Aug 2025                                                |
|                                                            | Updated CHMP Rapporteur AR                                 | 28 Aug 2025                                                | 28 Aug 2025                                                |
|                                                            | PRAC outcome                                               | 2 Sept 2025                                                | 2 Sept 2025                                                |
|                                                            | Start of CHMP written procedure                            | 2 Sept 2025                                                | 2 Sept 2025                                                |
|                                                            | CHMP Outcome                                               | 4 Sept 2025                                                | 4 Sept 2025                                                |
|                                                            | Submission of responses                                    | 29 Sep 2025                                                | 29 Sep 2025                                                |
|                                                            | Restart                                                    | 30 Sep 2025                                                | 30 Sep 2025                                                |
|                                                            | CHMP Rapporteur AR                                         | 03 Nov 2025                                                | 03 Nov 2025                                                |
|                                                            | CHMP comments                                              | 17 Nov 2025                                                | 17 Nov 2025                                                |
|                                                            | Updated CHMP Rapporteur AR                                 | 20 Nov 2025                                                | 21 Nov 2025                                                |
|                                                            | Start of CHMP written procedure                            | 25 Nov 2025                                                | 25 Nov 2025                                                |
|                                                            | CHMP Outcome                                               | 27 Nov 2025                                                | 27 Nov 2025                                                |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 5                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| 2. Overall conclusion and impact on the benefit/risk balance.....................                                          | 5                                                                                                           |
| 3. Recommendations...................................................................................                      | 7                                                                                                           |
| 4. EPAR changes .........................................................................................                  | 7                                                                                                           |
| Annex: Rapporteur's assessment comments on the type II variation .........                                                 | 9                                                                                                           |
| 5. Introduction..........................................................................................                  | 10                                                                                                          |
| 6. Clinical Immunogenicity aspects...........................................................                              | 10                                                                                                          |
| 6.1. Methods - analysis of data submitted                                                                                  | ..................................................................10                                        |
| 6.1.1. Study design                                                                                                        | .................................................................................................10         |
| 6.1.2. Study participants                                                                                                  | ..........................................................................................11                |
| 6.1.3. Study interventions                                                                                                 | ........................................................................................13                  |
| 6.1.4. Prior and Concomitant medications...................................................................14              |                                                                                                             |
| 6.1.5. Objectives and endpoints                                                                                            | ................................................................................15                          |
| 6.1.6. Immunogenicity assessment............................................................................16             |                                                                                                             |
| 6.1.7. Sample size...................................................................................................18    |                                                                                                             |
| 6.1.8. Randomization, blinding and stratification..........................................................18              |                                                                                                             |
| 6.1.9. Statistical methods.........................................................................................19      |                                                                                                             |
| 6.2. Results............................................................................................................21 |                                                                                                             |
| 6.2.1. Conduct of the study                                                                                                | ......................................................................................21                    |
| 6.2.2. Participant flow and numbers analysed..............................................................21               |                                                                                                             |
| 6.2.3. Baseline                                                                                                            | data.................................................................................................23     |
| 6.2.4. Outcomes and estimation................................................................................25           |                                                                                                             |
| 6.3. Discussion                                                                                                            | .......................................................................................................32   |
| 7. Clinical Safety aspects...........................................................................                      | 35                                                                                                          |
| 7.1. Methods - analysis of data submitted ..................................................................35             |                                                                                                             |
| 7.1.1. Overall Extent of Exposure                                                                                          | ..............................................................................36                            |
| 7.1.2. Demographic and Other Characteristics of Study Population                                                           | .................................36                                                                         |
| 7.2. Results............................................................................................................36 |                                                                                                             |
| 7.2.1. Common Adverse Events.................................................................................38            |                                                                                                             |
| 7.2.2. Deaths                                                                                                              | .........................................................................................................46 |
| 7.2.3. Other Serious Adverse Events..........................................................................46            |                                                                                                             |
| 7.2.4. Discontinuations Due to Adverse Events                                                                              | ............................................................46                                              |
| 7.2.5. Clinical laboratory evaluations..........................................................................46         |                                                                                                             |
| 7.2.6. Vital signs and physical findings                                                                                   | .......................................................................50                                   |
| 7.2.7. Safety in special groups and situations..............................................................50             |                                                                                                             |
| 7.3. Discussion                                                                                                            | .......................................................................................................53   |
| 8. Risk management plan..........................................................................                          | 54                                                                                                          |
| 8.1. Overall conclusion on the RMP                                                                                         | ............................................................................55                              |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| 9. Changes to the Product Information ..................................................... 55                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10. Request for supplementary information.............................................. 55                                                                                      |
| 10.1. Major objections .............................................................................................55                                                          |
| 10.2. Other concerns ...............................................................................................55                                                          |
| 11. Assessment of the responses to the request for supplementary information ............................................................................................... 56 |
| 11.1. Major objections .............................................................................................56                                                          |
| 11.2. Other concerns ...............................................................................................56                                                          |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 19 June 2025 an application for group of variations.

The following changes were proposed:

| Variations requested   | Variations requested                                                                                                                                                                                  | Type              |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| C.I.4                  | C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data                                           | Variation type II |
| C.I.11.b               | C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* | Variation type II |

A grouped application consisting of: C.I.4: To update sections 4.4, 4.8, 5.1 of the SmPC to include safety and immunogenicity data following the results from study referred to as V920-015 ACHIV, listed as a category 3 study in the RMP; this is a Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to evaluate the safety and immunogenicity of the V920/Ervebo (rVSVΔG -ZEBOV-GP) Ebola virus vaccine candidate in HIV-Infected adults and adolescents. The RMP version 2.1 has also been submitted. In addition, the Applicant took the opportunity to remove the complete list of local representatives, as suggested by the EMA during the review of specimens for the current ongoing renewal. Instead, the contact details of the MAH are included for ease of contact.  C.I.11.b: Submission of an updated RMP version 2.1 in order to summarize the safety and effectiveness of Ervebo administered in the context of Expanded Access Protocol (EAP) 5 compassionate ring vaccination study.

The requested variation(s) proposed amendments to the Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

At the time of submission of the application, the PIP P/0315/2024 was completed.

The PDCO issued an opinion on compliance for the PIP P/0315/2024.

## 2. Overall conclusion and impact on the benefit/risk balance

Ervebo (V920 or rVSVΔG -ZEBOV-GP, live) is a single dose replication-competent attenuated live vaccine based on genetically engineered recombinant vesicular stomatitis virus (rVSV) vector, which has the gene encoding for the vesicular stomatitis virus (VSV) glycoprotein (GP) deleted from its RNA and replaced with the gene encoding for the Zaire Ebola Virus (ZEBOV) GP (rVSVΔG -ZEBOV-GP).

In the EU, Ervebo is indicated for active immunisation of individuals 1 year of age and older to protect against Ebola Virus Disease (EVD) caused by ZEBOV.

In this application, the MAH submitted the clinical study report (CSR) of clinical study V920-015, a Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of 1 or 2 doses of the V920 Ebola Virus Vaccine Candidate in adolescents and adults 13 to 70 years of age (inclusive) living with human immunodeficiency virus (HIV). Amendments to SmPC sections 4.4, 4.8 and 5.1 based on safety and immunogenicity results of study V920-015 are requested by the MAH.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

This submission fulfils several obligations including the final study in the EU Paediatric Investigation Plan (PIP), the additional risk minimisation activity for immunocompromised individuals included in the Risk Management Plan (RMP), and the post authorisation measure (PAM) REC from Extension of indication procedure EMEA/H/C/004554/II/0025.

In study V920-015, adolescents and adults 13 to 70 years of age (inclusive) living with a controlled HIV infection (defined as individuals on antiretroviral therapy with undetectable HIV loads and CD4+ T cell counts above 200 cell/mm3) received either 1 or 2 doses of V920 or placebo. Participants were followed for humoral immune responses at different time-points (Day 28, Month 6 and Month 12 with additional time-points for those in the 2-dose group) and for safety through 1 year after vaccination (1 year after first vaccination for those in the 2-dose group). A total of 250 participants in Cohorts 1 to 5 (201 in the pooled V920 group, 49 in the pooled placebo group) were included in the immunogenicity and safety population (including in the V920 group: 52 adolescents and 149 adults; 100 females and 101 males).

Humoral immune response results of study V920-015 showed that administration of a single dose of V920 induces GP-specific binding and neutralizing antibody as observed at Day 28 post-vaccination in adolescents and adults living with a controlled HIV infection. At 1-year post-vaccination, antibody levels were still higher than pre-vaccination. Administration of a second dose of V920 at Day 56 after the primary dose resulted in a transient boost in binding and neutralizing antibody responses, which declined at Month 12 to levels comparable to those detected after a single primary dose. In the absence of immunological correlates of protection (ICP), the clinical relevance of those immunogenicity results is unknown.

Unexpected trends in the evolution over time of the measured binding and neutralizing antibody responses were noted, with higher antibody levels detected at later time-points. These unexpected trends in the evolution of antibody levels were also notable in other clinical studies, but they were more pronounced in study V920-015. The MAH stated that this might be related to the maturation of the immune response, which can result in a gradual increase or sustained elevation of antibody titres months after vaccination, even in the absence of additional antigen exposure.

In study V920-015, the safety profile of the V920 vaccine in 52 adolescents and 149 adults living with a controlled HIV infection was generally consistent with the known safety profile of Ervebo.

In the pooled V920 group (Cohorts 1 to 5 combined), the reported common injection-site adverse reactions reported within 14 days postvaccination (Vaccination 1 for Cohort 5) were injection-site pain (64.7%), swelling (5.5%), and erythema (4.5%). The reported systemic adverse reactions were headache (54.2%), fatigue  (45.3%),  feeling  hot  (25.4%),  arthralgia  (24.9%),  myalgia  (17.4%),  chills  (16.4%),  nausea (13.9%), hyperhidrosis (12.9%), abdominal pain (12.4%), diarrhoea (8.5%), pyrexia (5.5%), rash (4%), and blister (1%). In the pooled V920 group, the frequencies of the reported solicited events specific to postvaccination within 42 days after vaccination were, overall, slightly higher than the frequencies observed 14  days  after  vaccination:  arthralgia  (28.9%),  pyrexia  (10.4%),  rash  (6%),  and  blister  (1.5%).  The frequencies observed after 1-year postvaccination (1 year after Vaccination 1 for Cohort 5) were similar to those at 42-days postvaccination (after Vaccination 1 for Cohort 5), and no clinically meaningful unsolicited event was reported.

Overall, no clinically meaningful differences in adverse event (AE) profiles were observed with safety analyses presented by subgroup by cohort (different CD4+ T cell counts in adults), by age category (adults or adolescents) and by sex (males or females). The results should be interpreted with caution due to the small sample sizes in the subgroups (by cohort around 40 vaccinated with V920 and 10 with placebo; 52 adolescents and 149 adults; 100 females and 101 males).

Concerning vaccine viraemia and shedding (saliva and urine), submitted results in terms of proportions of participants with viraemia or shedding at different time-points post-vaccination and quantitative data are

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

comparable between participants of V920-015 living with a controlled HIV infection and already available data from previous study conducted in HIV seronegative healthy individuals.

The benefit-risk balance of Ervebo remains positive.

## 3. Recommendations

Based on the review of the submitted data, this application regarding the following change:

| Variations approved   | Variations approved                                                                                                                                                                                   | Type              |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| C.I.4                 | C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data                                           | Variation type II |
| C.I.11.b              | C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* | Variation type II |

A grouped application consisting of: C.I.4: To update sections 4.4, 4.8, 5.1 of the SmPC to include safety and immunogenicity data following the results from study referred to as V920-015 ACHIV, listed as a category 3 study in the RMP; this is a Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to evaluate the safety and immunogenicity of the V920/Ervebo (rVSVΔG -ZEBOV-GP) Ebola virus vaccine candidate in HIV-Infected adults and adolescents. The RMP version 3.0 has also been submitted. In addition, the Applicant took the opportunity to remove the complete list of local representatives, as suggested by the EMA during the review of specimens for the current ongoing renewal. Instead, the contact details of the MAH are included for ease of contact. C.I.11.b: Submission of an updated RMP version 3.0 in order to summarize the safety and effectiveness of Ervebo administered in the context of Expanded Access Protocol (EAP) 5 compassionate ring vaccination study.

is recommended for approval.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan P/0315/2024 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, IIIB and to the Risk Management Plan are recommended.

## 4. EPAR changes

The table in the 'Steps after' module of the EPAR will be updated as follows:

## Scope

Please refer to the Recommendations section above

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Summary

Please refer to Scientific Discussion 'Ervebo-H-C-004554-II-EMA/VR/0000280470'

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Annex: Rapporteur's assessment comments on the type II variation

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 5. Introduction

Ervebo (V920 or rVSVΔG -ZEBOV-GP, live) is a single dose replication-competent attenuated live vaccine based on genetically engineered rVSV vector, which has the gene encoding for the VSV GP deleted from its RNA and replaced with the gene encoding for the ZEBOV GP (rVSVΔG -ZEBOV-GP).

To date, Ervebo has been approved in the EU, the US, Canada, Switzerland, UK, and 11 African countries and it is prequalified by the WHO. In the EU, ERVEBO is indicated for active immunization of individuals 1 year of age and older to protect against EVD caused by Zaire Ebola virus, to be used in accordance with official recommendations.

Within this submission, the MAH submitted the CSR of clinical study V920-015, which fulfils several obligations including being the final study in the EU Paediatric Investigation Plan (EMEA-001786-PIP0115-M03), addressing the RMP additional risk minimization activity for immunocompromised individuals, and fulfilling PAM REC from Extension of indication procedure EMEA/H/C/004554/II/0025: ' Results of V920-015 (CSR expected in 2024) should be submitted as soon as available'.

Within this procedure, the MAH also submitted a clinical overview summarizing the safety and effectiveness of V920 administered in the context of the Expanded Access Protocol 005 (EAP5) Compassionate ring vaccination study to evaluate the safety of the Ebola vaccine in the DRC from AUG2018 through JUN-2020 in an outbreak setting.

This clinical overview was already submitted by the MAH within procedure EMEA/H/C/004554/REC025.1 in response to question 1 received from procedure EMEA/H/C/004554/REC/025. More specifically, in response to the request for submission of a comprehensive overview of effectiveness data (including a critical discussion of the available effectiveness data) including - as a minimum - all effectiveness data generated under V920-EAP5.

As specified in the cover letter, study V920-EAP5, whilst already submitted to the EMA to fulfill PAM REC 23 (REC 025.1), is re-submitted to present and readdress the RMP additional pharmacovigilance activity for exposure during pregnancy/lactation .

As no new effectiveness data was submitted, EAP5 effectiveness data are not addressed in section 6 of this AR.

Safety data from EAP5 - presented in the clinical overview that was already submitted in response to question 1 received from procedure EMEA/H/C/004554/REC/025 - were already summarized and discussed within procedure EMEA/H/C/004554/REC026.1. These are therefore not addressed in section 7 of this AR.

## 6. Clinical Immunogenicity aspects

## 6.1. Methods - analysis of data submitted

## 6.1.1. Study design

V920-015 is a Phase 2 Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of 1 or 2 doses of the V920 (rVSVΔG -ZEBOV-GP) Ebola Virus Vaccine Candidate in adolescents and adults 13 to 70 years of age (inclusive) living with HIV.

The study was conducted in Canada, Burkina Faso and Senegal.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The study was designed to enrol sequentially 5 study cohorts based on CD4+ T cell counts and age. A total of 50 adult (cohort 1 to 3), or adolescent (cohort 4) or adult and adolescent (cohort 5) participants was planned to be enrolled per cohort. Participants in Cohorts 1 to 4 were to be randomly assigned to receive 1 dose of V920 or placebo in a ratio of 4:1. Participants in Cohort 5 were to be randomly assigned to receive 1 dose of V920 or placebo in a ratio of 4:1 on Day 0, followed by booster vaccination at Day 56 (matching vaccine).

V920-015 study design is represented in Figure 1.

<!-- image -->

CD4=clusterofdifferentiation4;D-Day

Note: Cohorts 1 to 4 (1-dose groups) received V920 or placebo at Day 0. Cohort 5 (2-dose group) received V920 or placebo on Day 0 and Day 56.

## Figure 1: V920-015 Trial diagram

Blood samples for immunogenicity testing were obtained from all randomized participants in all cohorts at baseline (Day 0) before vaccination and at Day 28, Month 6, and Month 12. For the 2-dose group, blood samples were also collected at Days 56 (before Vaccination 2) and 84.

Safety and tolerability were assessed by clinical review of AEs and other relevant parameters (e.g. laboratory tests and vital signs) for all participants through 1-year postvaccination.

## 6.1.2. Study participants

Adolescents and adults with HIV-infection who were 13 to 70 (inclusive) years of age, on antiretroviral therapy with an undetectable viral load (&lt;40 c/mL), had CD4 Tcell counts ≥ 200 cells/mm3, did not have a history of infection with a filovirus or VSV, and had not participated in a filovirus vaccine study or received a VSV-vectored vaccine, were eligible for the study.

Per protocol, enrolment was to be of ~100 subjects from 2 sites in Canada (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and of ~150 subjects from 2 sites in Africa (Centre MURAZ, Burkina Faso and Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formations (IRESSEF), Dakar, Senegal).

## Inclusion criteria

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- HIV-infected adult or adolescent male or non-pregnant, non-breastfeeding female, ages 13 to 70 (inclusive) at the time of screening;
- On antiretroviral therapy with an undetectable viral load (&lt;40 copies/mL);
- CD4 Tcell counts ≥200 cells/mm3 ;
- Written informed consent (subject or parent) and assent (adolescent), after reading the consent form and having adequate opportunity to discuss the study with an investigator or a qualified designee;
- Free of clinically significant health problems that could affect the safety of the participant, as determined by the Investigator by pertinent medical history and clinical examination prior to entry into the study;
- Available, able, and willing to participate for all study visits and procedures;
- Males and females who are willing to practice abstinence from sexual intercourse, or are willing to use effective methods of contraception, from at least 30 days prior to vaccination until 2 months after vaccination.
- a) If the partner is NOT of childbearing potential, the couple will only be required to use condoms, without other adjunctive contraception.
- b) For this study, a woman is considered of childbearing potential unless postmenopausal ( ≥ 1 year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)
- c) Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label for example:
- i. Male condoms PLUS
- ii. Oral contraceptives, either combined or progestogen alone
- iii. injectable progestogen
- iv. implants of etenogestrel or levonorgestrel
- v. oestrogenic vaginal ring
- vi. percutaneous contraceptive patches
- vii. intrauterine device or intrauterine system
- Be willing to minimize blood and body fluid exposure of others for 8 weeks after vaccination
- a. Avoiding the sharing of needles, razors, or toothbrushes
- b. Avoiding open-mouth kissing

## Exclusion criteria

- History of prior infection with a filovirus or prior participation in a filovirus vaccine study;
- History of prior infection with VSV or receipt of a VSV-vectored vaccine;
- Presence of any febrile illness or any known or suspected acute illness on the day of any first immunization (subject may be rescheduled);
- Clinical manifestations of systemic diseases considered by the investigator to impact safety or immunogenicity;
- Receipt of systemic glucocorticoids (a dose ≥ 20 mg/day prednisone or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 12 months;

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- Receipt of any investigational drug within 12 months of vaccination;
- Receipt of any live virus vaccine within 42 days prior to study entry or any other (non-live virus) vaccine within 14 days prior to study entry;
- History of sensitivity to any component of study vaccines per investigator brochure or package insert;
- Any baseline laboratory screening tests which is outside of acceptable range as defined in the protocol (local site reference ranges): ALT, AST, creatinine, hemoglobin, platelet count, total white blood cell count, urine protein, urine occult blood, urine glucose AND considered clinically significant by the clinical investigator. The following five screening parameters have limits set:
- a) absolute lymphocyte count ≥ 1000 cells/mm3
- b) hemoglobin not greater than 1.5 grams below the lower limit of the normal reference range at the local laboratory
- c) ALT, AST not greater than 2 to 2.5 times the upper limit at the local laboratory
- d) Platelet count ≥ 125,000 and ≤ 550,000
- To exclude transient laboratory abnormalities, the investigator may repeat a specific test (E.g. hemoglobin) once during the screening period (I.e. a maximum of two tests), , and if the repeat test is normal, subject may be enrolled;
- Have an active malignancy or history of metastatic or hematologic malignancy except non-melanoma skin cancers;
- Suspected or known alcohol and/or illicit drug abuse within the past 5 years;
- Moderate or severe illness and/or fever &gt;101°F (38.3ºC) orally or &gt; 100°F (37.8ºC) axillary within one week prior to vaccination;
- Pregnant or breastfeeding female, or female who intends to become pregnant during the study period;
- Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period;
- Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study.

## 6.1.3. Study interventions

Per Protocol, one dose of ≥ 2 x 10E7 pfu of the study vaccine or placebo was to be administered at D0 in all Cohorts. In Cohort 5, a second dose of matching vaccine ( ≥ 2 x 10E7 pfu/ml) or placebo was to be administered at Day 56. Vaccination was to be given on the day of treatment allocation/randomization or as close as possible to the date on which the subject is allocated/assigned. Study interventions are summarized in Table 1.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 1: Trial Treatment/Vaccination

| Vaccine              | Dose/Potency     | Dose Frequency                         | Route of Administration   | Regimen/Treatment Period/Vaccination Regimen       | Use              |
|----------------------|------------------|----------------------------------------|---------------------------|----------------------------------------------------|------------------|
| V920                 | ≥2x107PFU in 1mL | Once in cohorts 1- 4/Twice in Cohort 5 | IM                        | Visit 1, D0 and Visit 7 (Day 56), where applicable | Experimental     |
| Normal saline (0.9%) | 1 ml             | Once in cohorts 1- 4/Twice in Cohort 5 | IM                        | Visit 1, D0 and Visit 7 (Day 56), where applicable | Placebo- control |

Subjects in Cohort 5 will receive two doses ofV920≥2x107pFU or two doses of normal saline placebo (0.9%) on D0 and D56.

Information for the V920 vaccine lots provided by the MAH and administered in Study V920-015 is provided in a table submitted in response to RSI to the CHMP comment 2 (Table 2). Distribution of the product by cohort was not submitted (would require manual review, extraction, compilation and validation of source documentation in the different clinical sites, not pursued). It appears that 3 different V920 Drug Product Lots were used in study V920-015, all had a potency ≥ 2 x 10E7 pfu/mL.

Placebo was sterile normal saline (sodium chloride 0.9% for injection, US Pharmacopeia, preservative free).

Table 2: V920 drug lot numbers, actual potencies, and country each lot was shipped to

| Lot Number                                           | Potency                                  | Country Vaccine Shipped To               |
|------------------------------------------------------|------------------------------------------|------------------------------------------|
| WL00067464 (underlying drug product lot WL00063635)  | 1.3 x 10* pfu/mL                         | Burkina Faso, Senegal                    |
| 0000852249 (underlying drug product  lot WL00067929) | 3.0 x 10* pfu/mL                         | Burkina Faso, Senegal, Canada            |
| WL00061392 (underlying drug product lot WL00061283)  | 5.4 x 107 pfu/mL                         | Canada                                   |
| 1 Per Certificate of Analysis at release             | 1 Per Certificate of Analysis at release | 1 Per Certificate of Analysis at release |

## 6.1.4. Prior and Concomitant medications

Prior medication taken by the subject within 6 months before dose of trial vaccination and medication taken by the subject during the trial were to be recorded.

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing trial. The final decision on any supportive therapy or vaccination rests with the investigator and/or the subject's primary physician.

Listed below are specific restrictions for concomitant therapy or vaccination following each vaccination:

1. Systemic glucocorticoids (a dose ≥ 20 mg/day prednisone or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within twelve months;

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

2. Any investigational drug within twelve months;
3. Any live virus concomitant vaccinations within 42 days;
4. Any other (non-live) concomitant vaccinations within 14 days.

## 6.1.5. Objectives and endpoints

The objectives, hypotheses, and endpoints are provided in Table 3.

Table 3: V920-015 objectives, hypotheses and endpoints

| Primary Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PrimaryEndpoints                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Evaluate the safety and tolerability of V920in HIV-infected adults and adolescents.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Solicited local and systemic AEs for 14 days aftereachvaccination Fever, arthritis, arthralgia, rash, and blisters/vesicular lesions for 42 days after eachvaccination Unsolicited AEs for 42 days after each vaccination Vaccine-related SAEs through to Day 365 Changes in vital signs (eg, blood pressure, heart rate, respiratory rate, and temperature) Changes in clinical laboratory values |
| Evaluate the immunogenicity of V920 via ZEBOV-specific antibody responses inducedbyV920inHIV-infectedadults and adolescents. Hypotheses: The GMT ofGP-ELISA inV920vaccinated HIV-infected adults and adolescentswillbe superior to the GMT of the GP-ELISA in placebovaccinated HIV-infected adults and adolescents at Day 28 in Cohorts 1 to 5 combined. TheGMTofGP-ELISAinV920vaccinated HIV-infected adults and adolescentswillbe superior to the GMT of the GP-ELISA in placebo vaccinated HIV-infected adults and adolescents Day 28 after the last dose of vaccine (equivalent to Day 84 from first dose) in Cohort 5. | GMTs at Day 28 after randomization (initial vaccination) in Cohorts 1 to 5 combined, as measured by GP-ELISA GMTs at Day 28 after last dose of vaccine, as measured by GP-ELISA (Cohort 5)                                                                                                                                                                                                         |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| SecondaryObjectives                                                                                                                                                                           | Secondary Endpoints                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Evaluate ZEBOV-specific antibody responses induced by V920 through Day 180 (Month 6) and Day 365 (Month 12).                                                                                  | GMTs,GMFIs,and seroresponse rates through 1-year postvaccination in Cohorts 1 to 5, as measured by GP-ELISAandPRNT                                                                                                                                                                                                                                                                                  |
| Evaluate the safety and tolerability of 2 doses of V920 in HIV-infected adults and adolescents administered56days apart.                                                                      | Solicited local and systemic AEs for 14 days aftereachvaccination Fever, arthritis, arthralgia, rash, and blisters/vesicular lesions for 42 days after each vaccination Unsolicited AEs for 42 days after each vaccination Vaccine-related SAEs through to Day 365 Changes in vital signs (eg, blood pressure, heart rate, respiratory rate, and temperature) Changes in clinical laboratory values |
| Evaluate the immunogenicity of 2 doses of V920 administered 56 days apart via ZEBOV-specific antibody responses induced by V920 at Day 28 post-dose 2 in HIV-infected adults and adolescents. | GMTs, GMFIs, and seroresponse rates at Day 28post-dose 2 in Cohort 5,as measured by GP-ELISA and PRNT                                                                                                                                                                                                                                                                                               |
| Evaluate VSV viremia and shedding after administration ofV920.                                                                                                                                | Vaccine viral shedding                                                                                                                                                                                                                                                                                                                                                                              |
| Evaluate the impact of V920 on HIV viral load, CD4 counts, and CD4/CD8 ratio.                                                                                                                 | Changes in clinical laboratory values                                                                                                                                                                                                                                                                                                                                                               |

There were also tertiary objectives specified in the Protocol V4.0 (dated 17 September 2019), but not in SAP. These are: (1) Evaluate Ebola-specific CD8+ T cell responses; (2) Evaluate B-cell repertoire; (3) Evaluate the impact of V920 on HIV viral reservoir.

Based on CSR, none of these tertiary objectives were explored.

## 6.1.6. Immunogenicity assessment

For immunogenicity assessment, samples were tested at 2 locations in the US.

Immunogenicity results reported in V920-015 were generated from a validated proprietary glycoprotein enzyme-linked immunosorbent assay GP-ELISA and a validated plaque reduction neutralization test (PRNT).

Both GP-ELISA and PRNT assays are described below based on the information provided in the SAP.

Differently from other studies conducted previously, samples collected from participants from African sites were not gamma irradiated.

## Sample handling

Participants in Cohorts 1 to 4 (1-dose group) had immunogenicity serology samples collected at baseline and Day 28, Month 6, and Month 12 postvaccination.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Participants in Cohort 5 (2-dose group) had immunogenicity serology samples collected at baseline and Day 28, Day 56, Day 84, Month 6, and Month 12 after Vaccination 1. Samples starting at Day 56 are after Vaccination 2 for this 2-dose group.

Blood collection time points and day ranges - as specified in the SAP - are listed in Table 4.

Table 4: Blood Collection Time Points

| Time Points and Day Ranges   | V920-007 Children 6- 17 Years of Age   | V920-013   | V920-014a   | V920-015 Cohort 1-4   | V920-015 Cohort 5   |
|------------------------------|----------------------------------------|------------|-------------|-----------------------|---------------------|
| Baseline                     | <D0                                    | DO         | DO          | <D0                   | <DO                 |
| Day 1                        |                                        |            | D1          |                       |                     |
| Day 2 or 3                   |                                        |            | D2 or D3    |                       |                     |
| Day 7                        | D7                                     |            | D7          |                       |                     |
| Day 14                       | D14                                    |            | D14         |                       |                     |
| Day 28 / Month 1             | D28±7                                  | M1 ±7      | D28±7       | D28±3                 | D28±3               |
| Day 56                       | D56±7                                  |            | D56±7       |                       | D56±3               |
| Day 84 / Month 3             | D84±7                                  | M3±7       | D84±7       |                       | D56+28±3            |
| Day 180/ Month 6             | D180±14                                | M6 ±14     | D180 ±14    | D180±14               | D180±14             |
| Day 365 / Month 12           | D365±14                                | M12 ±14    | D365±14     | D365±28               | D365±28             |
| Month 18                     |                                        | M18 ±14    |             |                       |                     |

## Description of Assay Methods

Zaire  ebolavirus  (ZEBOV)  Anti-Glycoprotein  (GP)  Immunoglobulin  G  (IgG)  Human  Enzyme-Linked Immunosorbent Assay (GP-ELISA)

To measure and quantify total IgG antibodies against V920, an indirect GP-ELISA which utilizes a purified recombinant Ebola Zaire glycoprotein (rGP) as the coating antigen has been validated. Briefly, microtiter plates are coated with purified recombinant ZEBOV-rGP. Serum samples and controls are then incubated with the rGP coated wells allowing ZEBOV-GP specific antibodies to bind. A serial diluted reference standard, obtained from a pool of vaccinated human donors, is also included. Each well is then incubated with goat anti-human IgG horseradish peroxidase conjugate, which enzymatically reacts with the tetramethylbenzidine substrate to form a coloured solution. After incubation, the enzymatic reaction is stopped using a sulfuric acid solution. The optical density (OD) is measured on an ELISA plate reader and serum sample titer concentrations are calculated from the standard curve using a 4-parameter logistic (4PL) curve fit. Titers are reported as GP-ELISA units/mL (EU/mL).

## rVSVΔG -ZEBOV-GP Plaque Reduction Neutralization Test PRNT (PRNT60)

A PRNT assay has been validated to determine the neutralizing antibody levels in human sera following the administration of V920. In this assay, serum is diluted from 1:5 to 1:10,240 and mixed with an equal volume of diluted V920 for final dilutions of 1:10 to 1:20,480. Neutralization is allowed to proceed over an 18-hour period at 2-8ºC after which the serum/virus mixture is used to inoculate Vero cells

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

monolayers. Viral adsorption is done at 37±2ºC for 60 minutes followed by a methylcellulose overlay. The infected cells are incubated at 37±2ºC for 2 days. Plaques are visualized by crystal violet stain and are counted using the ViruSpot from Autoimmun Diagnostika GMBH (AID). Determination of the PRNT60 is based on inverse of serum sample dilution that reduced viral plaques by 60% compared to virus control.

Lower Limits of Quantification (LLOQ) are provided in Table 5. Immunogenicity values below LLOQ (&lt;LLOQ) were imputed as LLOQ/2.

Table 5: Lower Limits of Quantification (LLOQ) of the Validated Assays

## 6.1.7. Sample size

For immunogenicity assessment, there is 80% power to detect a Geometric Mean Ratio (GMR) of 1.6 (V920 GP-ELISA GMT of 58 EU/mL vs. Placebo GP-ELISA GMT of 36 EU/mL, the lower limit of quantification [LLOQ]) and 90% power to detect a GMR of 1.7 (V920 GP-ELISA GMT of 62 EU/mL) if comparing all five cohorts (N=200 V920 vs. N=50 Placebo) combined. This power analysis assumes a 10% dropout, a standard deviation of 1 on the log scale, and a 2-sided 5%.

There is 80% power to detect a GMR of 2.9 (V920 GP-ELISA GMT of 105 EU/mL) and 90% power to detect a GMR of 3.4 (V920 GP-ELISA GMT of 124 EU/mL) if comparing each cohort independently (N=40 V920 vs. N=10 Placebo). This power analysis assumes a 10% dropout, a standard deviation of 1 on the log scale, and a 2-sided 5%.

For safety assessment, there is 80% power to detect a 12% difference in event rates that occur with a frequency of 1% in the control group if comparing four cohorts (N=200 V920 vs. N=50 Placebo) combined and a 46% difference if comparing each cohort independently (N=40 V920 vs. N=10 Placebo).

## 6.1.8. Randomization, blinding and stratification

According to V920-015 Protocol Version 4.0, the study is a double-blind trial, and Sponsor, investigator, and subject will not know the vaccine administered until unblinding. Unblinding will be performed after the database is locked.

A participant may be unblinded during the course of the study if the PI deems that, for health purposes, the blind must be broken. Only in the case of an emergency, when knowledge of whether the participant has received the investigational product is essential for the clinical management or welfare of the participant, the investigator may authorize the unblinding of a participant's treatment assignment. If time permits, the investigator or qualified study staff designee is encouraged to contact the Sponsor coordinating PI, prior to breaking the blind.

Subjects were to be assigned randomly according to a computer-generated allocation schedule.

Participants were to be randomized 4:1 (study vaccine: placebo control) using centralized randomization, with a total of approximately 200 study vaccine recipients and 50 placebo control recipients.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

To satisfy the requirement that each site enrolls at least one placebo subject in each cohort, enrollment had to proceed until treatments have been randomized to at least one complete block of subjects (consisting of four subjects receiving treatment and one receiving placebo) at each site.

Treatment allocation/randomization was to be stratified by the 5 cohort groups:

- Cohort 1: Screening CD4 cell counts for adults: CD4 cells/mm3 ≥ 500
- Cohort 2: Screening CD4 cell counts for adults: CD4 cells/mm3 &gt;350 and &lt;500
- Cohort 3: Screening CD4 cell counts for adults: CD4 cells/mm3 ≥ 200 and ≤ 350
- Cohort 4: Screening CD4 cell counts for adolescents, age 13 to 17: CD4 cells/mm3 ≥ 200
- Cohort 5: Screening CD4 cell counts for adults and adolescents, age 13 to 17: CD4 cells/mm3 ≥ 200 with 2 doses.

All cohorts are stratified by site (two sites per cohort).

Cohort 5 was to be stratified by site, and by age group (adolescent vs. adult). Once three blocks of five adolescents have been enrolled, with at least one block at each site, the requirement to enroll at least 12 adolescents in Cohort 5 will be met.

## 6.1.9. Statistical methods

The MAH submitted a Statistical Analysis Plan outlining the statistical analysis strategy and procedures for the V920-007, V920-013, V920-014, and V920-015 studies. Based on revision dates, the submitted SAP is dated 27 September 2024, which is prior to the MSD Database Lock Date specified in the V920-015 CSR (17 October 2024).

## Analysis populations

The All Subjects as Treated (ASaT) population will be used for the analysis of safety data in this study. The ASaT population consists of all randomized subjects who received at least one dose of study vaccination. Subjects will be included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population. For most subjects this will be the treatment group to which they are randomized. Subjects who received incorrect study vaccine will be included in the treatment group corresponding to the study vaccine actually received.

The Per-Protocol population (PP) will serve as the primary population for the analysis of immunogenicity data in this study. The Per-Protocol population excludes subjects due to important deviations from the protocol that may substantially affect the results of the primary immunogenicity endpoint(s). For example, subjects who are seropositive at baseline will be excluded from the Per-Protocol population. All subjects who meet the inclusion criteria, were seronegative at baseline, and do not have a major protocol deviation will be included in the per-protocol analysis.

The final determination of subjects with major protocol deviations, and thereby the composition of the Per-Protocol population, will be made prior to the unblinding of the database for the primary CSR and will be documented in a separate memo.

A supportive analysis using the Full Analysis Set (FAS) population may be performed. The FAS population consists of all randomized subjects with serology data.

## Immunogenicity Analyses

Immunogenicity will be summarized as follows:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- The immunogenicity population will be the Per-Protocol (PP) population or the Full Analysis Set (FAS) population depending on if the PP population can be defined from the data received.
- Immunogenicity summaries for the GP-ELISA and PRNT may include:
- o Geometric Mean Titers (GMT);
- o Geometric Mean Fold Increase (GMFI) from baseline;
- o Seroresponse at any time during study and for each timepoint defined as:
-  GP-ELISA:
- Primary: 2-fold increase from baseline and ≥ 200 EU/mL
- Secondary: 4-fold increase from baseline
-  PRNT: 4-fold increase from baseline

For V920-015, hypotheses comparing GMTs between V920 to placebo in HIV-infected participants at Day 28 will be tested using ANOVA and a twosided test at α = 0.05 . The statistical criterion for successful demonstration of superiority requires the lower bound of the 2-sided 95% CI on the GMT ratio [V920 / Placebo] to be &gt;0.

No multiplicity adjustments were planned to be made. Generally, missing data were not imputed.

Summaries for some analyses are provided for the following subgroups:

- Age category (adolescents, adults);
- Male and Female;
- Africa and ex-Africa;
- Baseline GP-ELISA &lt;200 EU/mL and baseline GP-ELISA ≥ 200 EU/mL.

## Safety Analyses

Safety and tolerability will be summarized as follows:

- The safety population will be the All Participants as Treated (APaT) population.
- Safety and tolerability will be assessed by clinical review of adverse events (AEs) and other relevant parameters (e.g., vaccine viral shedding, laboratory tests and vital signs)

Safety summaries will include counts and percentages of subjects with AEs and other relevant safety outcomes. For continuous safety measures summary statistics for baseline, on-treatment, and change from baseline values will be provided if relevant data are received.

## Changes from protocol-specified analyses

The following changes to the planned analyses were not previously described in a protocol amendment or SAP revision:

- The SAP stated that the CD4/CD8 ratio would be evaluated if relevant data were received. The CD4/CD8 ratio was not evaluated because CD8 data were not received.
- The SAP stated that the LLOQ for PRNT is 35. For measurements below the LLOQ, ½ LLOQ was planned to be used for the calculation of GMT, fold-rise, and seroresponse.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

In the data received, PRNT measurements less than the LLOQ and above the LLOD (20) were reported. Ten measurements ranging from 21 to 35 were included in the dataset. These 10 measurements were analyzed using their actual values. Measurements labeled '&lt;LLOQ' were analyzed as ½ LLOQ (½ x 35).

No changes were made after study unblinding.

## 6.2. Results

## 6.2.1. Conduct of the study

The original V920-015 study protocol was amended 5 times.

Based on amendment history as specified in CT14B\\_ACHIV-Ebola Protocol Version 4.0, protocol version 2.7 (11-MAY-2017) was active at the start of recruitment (first participant first visit dated 01-NOV-2017). Subsequent amendments had an impact on applied inclusion/exclusion criteria. In protocol version 3.0 (10-JAN-2018) inclusion age was increased to 70 years of age and exclusion of healthcare workers was removed. In protocol version 4.0 (17-SEP-2019), exclusion criteria were revised to allow enrolment of participants with screening hematologic and chemistry values outside of normal site reference ranges, if deemed not clinically significant by the clinical investigator; laboratory sample collections were revised, and protocol was amended to clarify that a participant who is not eligible for an earlier cohort may be screened for eligibility for a subsequent cohort.

## 6.2.2. Participant flow and numbers analysed

First participant first visit was on 01-NOV-2017 and last participant last visit was on 03-MAR-2023. The analyses presented in the submitted CSR (revised report date 16 May 2025) are based on a database lock dated 17-OCT-2024.

## Participant disposition

In total (Cohorts 1 to 5 combined), 251 participants were randomized (202 in the V920 group, 49 in the placebo group) in study V920-015 across 4 study sites in 3 countries. All randomized participants received at least 1 dose of study intervention, except 1 V920 participant in Cohort 1 who was randomized but not vaccinated and discontinued the study.

Three participants (2 participants in Cohort 1 and 1 participant in Cohort 2) discontinued the study due to loss to follow-up.

The majority of the participants were randomized at the site in Burkina Faso (152/251; 60.6%), 73/251 (29.1%) were randomized at the site in Senegal and 26/251 (10.4%) in Canada (Table 14.1-7 of CSR). This is different from what originally planned per protocol. Namely planned enrolment was of ~100 subjects from Canadian sites and of ~150 subjects from African sites.

## Numbers analysed

A total of 250 participants in Cohorts 1 to 5 (201 in the pooled V920 group, 49 in the pooled placebo group) were included in the immunogenicity and safety populations (Table 6 and Table 7). The participant randomized but not vaccinated was excluded from the immunogenicity and safety analyses.

Participants Accounting for the GP-ELISA Per-Protocol Immunogenicity Population by Vaccination Group for All Randomized or Enrolled Participants of Cohort 1 to Cohort 5 are summarized in Table 6.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Participants Accounting for the PRNT Per-Protocol Immunogenicity Population by Vaccination Group for All Randomized or Enrolled Participants of Cohort 1 to Cohort 5 are summarized in Table 7.

No participant was excluded from the Per Protocol population due to a protocol deviation.

In the 1-dose V920 group (Cohorts 1 to 4 combined) 3 participants were missing baseline serology samples for the GP-ELISA analyses and 2 participants were missing Month 12 serology samples for the GP-ELISA and PRNT analyses.

In the placebo group (Cohorts 1 to 5 combined), one participant was missing Day 28 serology and one participants was missing Month 12 serology (both for GP-ELISA and PRNT analyses).

Table 6: Participants Accounting for the GP-ELISA Per-Protocol Immunogenicity Population by Vaccination Group (All Randomized or Enrolled Participants - Cohort 1 to Cohort 5)

|                                                                       | V920 1 Dose (N=162)   | V920 2 Doseb (N40)   | Pooled V920* (N202)   | Placcboc (N49)   |
|-----------------------------------------------------------------------|-----------------------|----------------------|-----------------------|------------------|
| Participants Vaecinated                                               | 161                   | 40                   | 201                   | 49               |
| Reasons for Exclusion From the Per-Protocol Immunogenicity Population | 1                     |                      | 1                     |                  |
| Participants not Vaccinated                                           |                       | 0                    |                       | 0                |
| Protocol Violation                                                    | 0                     | 0                    | 0                     | 0                |
| Included inPer-Protocol ImmunogenicityPopulation for GP-ELISA (EU/ml) | 161                   | 40                   | 201                   | 49               |
| Missing Serology Samples/Results at EachTime Point                    |                       |                      |                       |                  |
| Day 0 (Baseline)                                                      | 3                     | 0                    | 3                     | 0                |
| Day 28                                                                | 0                     | 0                    | 0                     | 1                |
| Day 56f                                                               | 161                   | 0                    | 161                   | 39               |
| Day 84f                                                               | 161                   | 0                    | 161                   | 39               |
| Month 6                                                               | 0                     | 0                    | 0                     | 1                |
| Month 12                                                              | 2                     | 0                    | 2                     | 2                |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 7: Participants Accounting for the PRNT Per-Protocol Immunogenicity Population by Vaccination Group (All Randomized or Enrolled Participants - Cohort 1 to Cohort 5)

|                                                                       | V920 1 Dose* (N=162)   | V920 2 Doseb (N=40)   | Pooled V920e (207=N)   | Placeboe (N=49)   |
|-----------------------------------------------------------------------|------------------------|-----------------------|------------------------|-------------------|
| Partieipants Vaecinated*                                              | 161                    | 40                    | 201                    | 49                |
| Reasons for Exclusion From the Per-Protocol Immunogenicity Population |                        |                       | 1                      |                   |
| Participants not Vaccinated                                           |                        | 0                     |                        | 0                 |
| Protocol Violation                                                    | 0                      | 0                     | 0                      | 0                 |
| Ineluded in Per-Protocol ImmunogenicityPopulation for PRNT            | 161                    | 40                    | 201                    | 49                |
| Missing Serology Samples/Results at Each Time Poinr                   |                        |                       |                        |                   |
| Day O (Baseline)                                                      | 0                      | 0                     | 0                      | 0                 |
| Day 28                                                                | 0                      | 0                     | 0                      | 1                 |
| Day 56f                                                               | 161                    | 0                     | 161                    | 39                |
| Day 84f                                                               | 191                    | 0                     | 161                    | 39                |
| Month 6                                                               | 0                      | 0                     | 0                      | 1                 |
| Month 12                                                              | 2                      | 0                     | 2                      | 2                 |

## Protocol deviations

Important protocol deviations were reported for 15 participants. No participant's data were excluded from analysis due to a protocol deviation. No protocol deviations were classified as a serious GCP compliance issue.

## 6.2.3. Baseline data

Demographics and Baseline Disease Characteristics for all participants randomized in all 5 cohorts combined are summarized in Table 8.

Relatively to the overall characteristics of the participants in all 5 cohorts:

- The majority of the participants were randomized at the site in Burkina Faso (152/251; 60.6%), 73/251 (29.1%) were randomized at the site in Senegal and 26/251 (10.4%) in Canada.
- The majority had a baseline GP-ELISA &lt;200 EU/mL (91.6%).
- The majority had CD4 ≥ 500 cells/mm3 (52.2%), the remaining participants were evenly distributed among participants with CD4 T cell counts ranging from 350-500 cells/mm3 (25.5%) and participants with CD4 T cell counts ranging from ≥200 to ≤350 cells/mm3 (22.3%).
- There were 65/251 (25.9%) participants aged 13-17 years, 103/251 (41%) aged 18-49 years, 63/251 (25.1%) aged 50-59 years, 18/251 (7.2) aged 60-65 years and 2/251 (0.8%) aged &gt;65 years. Proportions of participants with these age ranges were comparable in the arms.
- Similar proportions of male and female were recruitment, but there was a higher proportion of male participants who received V920 (50.5%) compared with placebo (38.8%), and a lower proportion of females who received V920 (49.5%) compared with placebo (61.2%).

Demographic characteristics by cohort were presented in the CSR. When considering the characteristics of participants of cohort 4 (Adolescents CD4 T cell counts ≥ 200 cells/mm3, 1 Dose) and of cohort 5 (Adults

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

and Adolescents CD4 T cell counts ≥ 200 cells/mm3, 2 Dose), it is noted that the majority had a CD4 T cell counts ≥500 cells/mm3 (43/50 (86%) in cohort 4 and 37/50 (74%) in cohort 5).

Table 8: Participant Characteristics (All Participants Randomized, Cohort 1 to Cohort 5)

<!-- image -->

|                                                                                                    | V920                        | V920                        | Placcbo                     | Placcbo                     | Total                       | Total                       |
|----------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Punkipnts inpopbtion                                                                               | 202                         |                             | 49                          | (%)                         | 251                         |                             |
| Ben                                                                                                |                             |                             |                             |                             |                             |                             |
| Male                                                                                               | 102 100                     | (50.5)                      | 19                          | (38.9)                      | 121                         | (48.2)                      |
| Femule Age (Yean)                                                                                  |                             | (49.5)                      |                             |                             |                             |                             |
| 13 to 17                                                                                           |                             | (257)                       | 30                          | (61.2)                      | 130                         | (51.8)                      |
| 18 1o 49                                                                                           |                             | (41.1)                      | 20                          | (26.9) (40.89)              | 100                         | (25.9) (11.0)               |
| 6905                                                                                               | 30                          | (24.8)                      | 13                          | (26.9)                      |                             | (25.1)                      |
| 60 to 65                                                                                           | 15                          | (7.4)                       | 1                           | (6.0)                       | 18                          | (.2)                        |
|                                                                                                    | 2                           | (1.0)                       |                             | (0.0)                       | 2                           | (0.8)                       |
| Mean                                                                                               | 20.1                        |                             | 18.1 16.9                   |                             | .9 16.7                     |                             |
| SD                                                                                                 | 16.8                        |                             |                             |                             | 4.0                         |                             |
| Meian Runge                                                                                        | 4.0 13t670                  |                             | 41.0                        | 13665                       | 13 6 70                     |                             |
| Race                                                                                               |                             |                             |                             |                             |                             |                             |
| Bbdk Or African Amerkan                                                                            | 181                         | (89.6)                      | 4                           | 68)                         | 215                         | (89.6)                      |
| Mutiple                                                                                            | 0                           | (0.0)                       |                             | (2.0)                       | 1                           | (0.4)                       |
| Asian, White Whitn                                                                                 | 0                           | (0.0)                       | 4                           | (2.0) (0.2                  | 2                           | (0.4) (10.0)                |
| Ehakily                                                                                            |                             | (104)                       |                             |                             |                             |                             |
| NotHiqpanic Or Latino                                                                              |                             | (100.0)                     | 48                          | (98.0)                      | 290                         | (9.6)                       |
| Mlang                                                                                              | 0                           | (0.0)                       |                             | (2.0)                       |                             | (0.4)                       |
| Counlry                                                                                            |                             |                             |                             |                             |                             |                             |
| Burina Faso                                                                                        | 122                         | (60.4)                      | 30                          | (61.2)                      | 152                         | (00.6)                      |
| Cansda                                                                                             | 21                          | (104)                       |                             | (10.2)                      | 26                          | (10.4)                      |
| Senepl                                                                                             | 9                           | (29.2)                      | 14                          | (28.0)                      | 71                          | (29.0)                      |
| Cohort                                                                                             |                             |                             |                             |                             |                             |                             |
| Cohot 1: Addt- CD4g500                                                                             | 41                          | (203)                       | 10                          | (20.4)                      | 51                          | (20.3)                      |
| cell/mm? Coho12:Addt-CD4>350                                                                       | 40                          | (19.8)                      | 10                          | (20.4)                      | 90                          | (19.9)                      |
| cdll/mm and<500 cell/mm Cohont 3: Adult - CD4 2200                                                 | 41                          | (203)                       | 9                           |                             |                             |                             |
| celle/mm and s350                                                                                  |                             |                             |                             | (18.40)                     | 50                          | (19.9)                      |
| sellemm' Cobort 4: Addesnt -                                                                       | 40                          | (19.8)                      | 10                          | (20.4)                      | 30                          | (661)                       |
| CD4>200 cell/m Cohort 5: Addlesrent * CDH2200 cell/mm                                              | 12                          | (5.9)                       | 3                           | (6.10)                      | 19                          | (og)                        |
| Cohart 5: Addli- CD4≥200 cell/mm?                                                                  |                             | (139)                       | 7                           | (14.3)                      | 33                          | (13.9)                      |
| Basellne GP-FLISA (EU/mL)                                                                          |                             |                             |                             |                             |                             |                             |
| 20                                                                                                 | 181                         | (90.6)                      | 47                          | (95.9)                      | 210                         | (91.6)                      |
| 2200                                                                                               | 15                          | (7.4)                       | 2                           | (4.0)                       | 17                          | (6.8)                       |
| Mleing                                                                                             | 4                           | (2.0)                       | 0                           | (0.0)                       | 4                           | (1.6)                       |
| CD4 (eell/mm)                                                                                      |                             |                             |                             |                             |                             |                             |
| 2500                                                                                               | 104                         | (51.5)                      | 27                          | (55.0)                      | 131                         | (51.2)                      |
| >350 and-≤500 2200 mnd g350                                                                        |                             | (25.7) (228)                | 12 10                       | (24.5) (20.4)               |                             | (2.5) (2.3)                 |
| CD4 (eel/mm)                                                                                       |                             |                             |                             |                             |                             |                             |
| Participant with-data                                                                              | 202                         |                             | 49                          |                             | 251                         |                             |
| Mean                                                                                               | 597.8                       |                             | 650.5                       |                             | 608.1                       |                             |
| SD Median                                                                                          | 294.6 514.5                 |                             | 473.5 566.0                 |                             | 518.0                       |                             |
| Range                                                                                              | 206 to 1580                 |                             | 230to 3087                  |                             | 490C 9 90                   |                             |
| Height (em) at Randomlation                                                                        |                             |                             |                             |                             | 10.6                        |                             |
| Participants with data                                                                             | 202                         |                             | 49                          |                             | 291 166.3                   |                             |
| Meun                                                                                               | 166.5                       |                             | 165.2                       |                             |                             |                             |
| SD Median                                                                                          | 10.7 1669                   |                             | 102 165.0                   |                             | 166.1                       |                             |
| Range                                                                                              | 136 to 192                  |                             | 1351o 186                   |                             | 135 to 192                  |                             |
| Weigh (kg) at Randenlzatien                                                                        |                             |                             |                             |                             |                             |                             |
|                                                                                                    |                             |                             | 49                          |                             | 6.2                         |                             |
| Participans withdaa                                                                                | 202 6.2                     |                             |                             |                             | 251                         |                             |
| Mean                                                                                               | 17.6                        |                             | 63.1 148                    |                             | 17.1                        |                             |
| SD Meian                                                                                           | 62.0                        |                             | 645                         |                             | 6.6                         |                             |
| Ranga                                                                                              | 29 to 114                   |                             |                             |                             | 29 6114                     |                             |
| DMIl (kgiu) at Ranombadon                                                                          |                             |                             |                             |                             |                             |                             |
| Paricipat with-daa                                                                                 | 202                         |                             | 49                          |                             | 291                         |                             |
| Mean                                                                                               | 22.6                        |                             | 229                         |                             | 22.7                        |                             |
|                                                                                                    |                             |                             | 22.8                        |                             |                             |                             |
| Range 131o42 14 o 4 13 6 42                                                                        | Range 131o42 14 o 4 13 6 42 | Range 131o42 14 o 4 13 6 42 | Range 131o42 14 o 4 13 6 42 | Range 131o42 14 o 4 13 6 42 | Range 131o42 14 o 4 13 6 42 | Range 131o42 14 o 4 13 6 42 |
| SD                                                                                                 |                             |                             | 4.4                         |                             | 91                          |                             |
| Median                                                                                             | 21.5                        |                             |                             |                             | 22.0                        |                             |
| SD-Sundard deviation.                                                                              | SD-Sundard deviation.       | SD-Sundard deviation.       | SD-Sundard deviation.       | SD-Sundard deviation.       | SD-Sundard deviation.       | SD-Sundard deviation.       |
| BMI-body maws indes (kg/m): CD4-cuser of differentiion 4(cellsmm): HIV-humn immunodeficiency vinus |                             |                             |                             |                             |                             |                             |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Reported medical history conditions for all 5 cohorts were generally comparable between the intervention groups. Reported concomitant medications for all 5 cohorts were generally comparable between the intervention groups. All participants received antivirals for systemic use.

## 6.2.4. Outcomes and estimation

Immunogenicity analyses were presented for cohorts 1 to 5 combined and also by cohorts and by subgroup for the following categories: age category (adult or adolescent), sex, baseline GP-ELISA, and country at randomization.

## Immunogenicity Results - GP-ELISA

## Superiority Analyses

## 1 Dose

In Cohorts 1 to 5 combined, the GP-ELISA estimated GMT at Day 28 post-vaccination (after Vaccination 1 for Cohort 5) was superior in the V920 group compared with the placebo group, with an estimated fold difference of 42.90 (95% CI: 31.49, 58.43; p&lt;0.001) Table 9 .

|          |                                          | ComparisonGroupA   | ComparisonGroupA   | ComparisonGroupA       | Comparison GroupB   | Comparison GroupB   | Comparison GroupB     | Estimated                               | p-value   | Conclusion       |
|----------|------------------------------------------|--------------------|--------------------|------------------------|---------------------|---------------------|-----------------------|-----------------------------------------|-----------|------------------|
| Assay    | Comparison Group A vs. Comparison GroupB | N                  |                    | Estimated GMT* (EU/mL) | N                   | n                   | Estimated GMT (EU/mL) | Fold Difference GroupA/Group B (95% CI) |           |                  |
| GP-ELISA | V920vs.Placebo                           | 201                | 201                | 1,223.1                | 49                  | 48                  | 28.5                  | 42.90 (31.49, 58.43)                    | <0.001    | Superiorityismet |

Table 9: Statistical Analysis of Superiority of V920 vs. Placebo for the GP-ELISA GMT Measured at Day 28 Postvaccination (GP-ELISA Per-Protocol Immunogenicity Population - Cohort 1 to Cohort 5)

<!-- image -->

## 2 Doses

In Cohort 5, the GP-ELISA estimated GMT at Day 28 after the last dose of vaccine (equivalent to Day 84 after Vaccination 1) was superior in the V920 group compared with the placebo group, with an estimated fold difference of 208.66 (95% CI: 115.57, 376.72; p&lt;0.001). Estimated GMTs (based on an ANOVA model with a response of the natural log of individual titres and fixed effects for intervention group) was of 8,416.0 EU/mL in the V920 group and of 40.3 EU/mL in the placebo group.

## Summary of GP-ELISA Geometric Mean Titers

The GP-ELISA GMTs for the 1-dose V920 (Cohorts 1 to 4 combined) and the 2-dose V920 (Cohort 5) groups are shown in Table 10.

Data indicate that:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- GMTs increased post-vaccination and remained elevated through Month 12. An unexpected trend of an increase in GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the V920 1-dose group is noted. This trend is also visualized in the submitted reverse cumulative distribution curves (Figure 2).
- Post-vaccination GMTs were higher than those of the pooled placebo group at all timepoints after baseline.
- The GP-ELISA GMTs for the 2-dose V920 group (Cohort 5) peaked at Day 84 and decreased to comparable concentrations as the 1-dose V920 group (Cohorts 1 to 4 combined) at Month 6 (higher GMT in the 2-dose group as compared to Month 6 GMT in the V920 1-dose group, but with overlapping 95% CI) and at Month 12.

Table 10: Summary of Geometric Mean Titres (GP-ELISA Per-Protocol Immunogenicity Population - Cohort 1 to Cohort 5)

| Assay Time Point   | V920 1 Dosca (N=161) GMT (m) [95% C1]               | V9202 Doseh (N=40) GMT (n) [95% C1]                 | Pooled V920c (N=201) GMT (n) [95% C1]               | Placcboc (N=49) GMT (n) [95% C1]    |
|--------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-------------------------------------|
| GP-ELISA           |                                                     |                                                     |                                                     |                                     |
| Bascline           | 33.2 (158) [28.1, 39.3]                             | 40.6 (40) [29.1, 56.5] 1,191.8 (40)                 | 34.6 (198) [29.8, 40.2] [1,068.0, 1,400.9]          | 28.3 (49) [21.0, 38.2]              |
| Day 28             | 1,231.1 (161)                                       |                                                     | 1,223.1 (201)                                       | 28.5 (48)                           |
| Day 56b            | [1,057.6, 1,433.0]                                  | [878.7, 1,616.3] 1,469.0 (40)                       | 1,469.0 (40)                                        | [21.6, 37.7] 32.8 (10)              |
| Day 84b            |                                                     | [1,122.3, 1,923.0] 8,416.0 (40) [6,461.9, 10,961.1] | [1,122.3, 1,923.0] 8,416.0 (40) [6,461.9, 10,961.1] | [19.2, 56.3] 40.3 (10) [23.8, 68.4] |
| Month 6            | 1,843.2 (161)                                       | 2,664.7 (40)                                        | 1,983.5 (201)                                       | 24.1 (48)                           |
| Month 12           | [1,592.2, 2,133.8] 2,158.2 (159) [1,846.6, 2,522.4] | [1,986.6, 3,574.3] 2,264.4 (40) [1,659.4, 3,090.1]  | [1,738.2,2,263.5] 2,179.2 (199) [1,896.2, 2,504.4]  | [18.5, 31.5] 24.8 (47) [18.6, 33.1] |

<!-- image -->

Figure 2: Reverse Cumulative Distribution Plot of GP-ELISA Titres by Timepoint (GP-ELISA PerProtocol Immunogenicity Population - V920 1 Dose - Cohort 1 to Cohort 4)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Month12

<div style=\"page-break-after: always\"></div>

In the CSR, GP-ELISA GMTs are presented separately by cohort and by subgroup (adults, adolescents, female, male, GP-ELISA baseline levels [ ≥200 EU/mL or &lt;200 EU/mL], African sites participants, Canadian sites participants).

The number of subjects in these analyses is limited to conclude on differences across cohort/subgroups, following trends are however noted (not discussed by MAH):

1. For cohort 1 (adults with CD4 T cell counts ≥500 cells/mm3) there was no notable trend towards an increase in GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the V920 1-dose ( Table 11 ), while for cohort 2 (adults with CD4 T cell counts ranging from 350-500 cells/mm3) and for cohort 3 (adults with CD4 T cell counts ranging from ≥200 to ≤350 cells/mm3) increases in GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the V920 1-dose group are marked (respectively Table 12 and Table 13).

For all adults (Cohort 1, 2 and 3), GP-ELISA GMTs rose from 32.3 EU/mL (N=118) at baseline to 1,170.8 (N=121) at Month 1, 1,724.0 (N=121) at Month 6 and 1,942.7 (N=119) at Month 12.

Table 11: Summary of Geometric Mean Titres (GP-ELISA Per-Protocol Immunogenicity Population) (Cohort 1 Adults CD4 ≥ 500, 1 Dose)

| Assay Time Point   | V920 (N=40) GMT (m) [95% CI]    | Placcbo (N=10) GMT (n) [95% C1]   |
|--------------------|---------------------------------|-----------------------------------|
| GP-ELISA           |                                 |                                   |
| Baseline           | 27.2 (38) [18.0, 41.0]          | 18.1 (10) [8.1, 40.2]             |
| Day 28             | 1,655.0 (40) [1,151.4, 2,378.9] | 18.1 (10) [8.7, 37.3]             |
| Month6             | 1,442.9 (40) [1,020.6,2.039.9]  | 18.1 (10) [9.0, 36.1]             |
| Month 12           | 1,428.1 (39) [971.9,2.098.3]    | 30.1 (9) [13.5, 67.0]             |

Table 12: Summary of Geometric Mean Titres (GP-ELISA Per-Protocol Immunogenicity Population) (Cohort 2 Adults CD4 &gt;350 and &lt;500, 1 Dose)

| Assay Time Point   | V920 (N=40) GMT (m) [95% C1]   | Placcbo (N=10) GMT (m) [95% CI]   |
|--------------------|--------------------------------|-----------------------------------|
| GP-ELISA           |                                |                                   |
| Bascline           | 33.8 (39) [25.2, 45.5]         | 19.6 (10) [10.9, 35.2] 26.8 (9)   |
| Day 28             | 1,124.6 (40) [821.0, 1,540.4]  | [13.8, 52.0]                      |
| Month6             | 2,387.0 (40) [1,717.2,3,318.2] | 21.7 (9) [10.8, 43.4]             |
| Month 12           | 2,755.0 (40) [2.004.9,3.785.9] | 20.5 (9) [10.5, 40.0]             |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 13: Summary of Geometric Mean Titres (GP-ELISA Per-Protocol Immunogenicity Population) (Cohort 3 Adults CD4 ≥ 200 and ≤ 350, 1 Dose)

| Assay Time Point   | V920 (N=41) GMT (n) [95% CI]             | Placcbo (N=9) GMT (m) [95% C1]   |
|--------------------|------------------------------------------|----------------------------------|
| GP-ELISA           |                                          |                                  |
| Baseline           | 36.2 (41)                                | 32.4 (9) [16.7, 62.9]            |
| Day 28             | [26.5, 49.4] 868.8 (41) [679.0, 1,111.6] | 29.7 (9) [17.5, 50.2]            |
| Month6             | 1,493.1 (41) [1,102.7,2.021.7]           | 22.7 (9) [11.9, 43.3]            |
| Month 12           | 1,849.3 (40) [1,361.6,2,511.7]           | 25.1 (9) [13.2,47.9]             |

2. Marked increase in GMTs at Month 12 as compared to Day 28 GMT in the V920 1-dose in cohort 4 (adolescents with CD4 T cell counts ≥200 cell/mm3), with Day 28 GMT of 1,432.8 EU/mL (95% CI: 1,091.0, 1,881.8 / n=40) and Month 12 GMT of 2,951.3 (95% CI: 2,142.2, 4,066.0 / n=40) as shown in Table 14.
3. Trends towards higher GMTs estimated in adolescents as compared to adults, which is consistent with data from the PREVAC study.
4. Trends towards higher GMTs estimated in female participants as compared to male participants, which is consistent with data from the PREVAC study.
5. When comparing GMTs measured after 1 dose of V920 from participants recruited in African sites (Table 15) with GMTs measured after 1 dose of V920 from participants recruited in Canadian sites (Table 16) it is noted that:
- a. Day 28 GMTs were comparatively higher in Canadian sites participants (2,058.4 EU/ml [95% CI: 1,367.2, 3,099.2] for n=20 subjects) as compared to African sites participants (1,144.5 EU/ml [95% CI: 973.4, 1,345.6] for n=141 subjects). At Canadian sites 20/21 participants who were administered V920 were from cohort 1 (adults with CD4 T cell counts ≥ 500 cells/mm3) and only 1 was from cohort 2.
- b. Marked increase in GMTs at Month 12 as compared to Day 28 GMT in the V920 1-dose in participants recruited from African sites, with Day 28 GMT of 1,144.5 EU/mL [95% CI:

Table 14: Summary of Geometric Mean Titres (GP-ELISA Per-Protocol Immunogenicity Population) (Cohort 4 Adolescents CD4 ≥ 200, 1 Dose)

| Assay Time Point   | V920 (N=40) GMT (m) [95% CI]    | Placcbo (N=10) GMT (m) [95%C]   |
|--------------------|---------------------------------|---------------------------------|
| GP-ELISA           |                                 |                                 |
| Bascline           | 36.3 (40) [25.8, 51.0]          | 37.0 (10) [18.7, 73.3]          |
| Day 28             | 1,432.8 (40) [1,091.0, 1,881.8] | 30.4 (10) [17.6, 52.4]          |
| Month 6            | 2,256.4 (40) [1,736.8,2.931.3]  | 24.7 (10) [14.6, 41.6]          |
| Month 12           | 2,951.3 (40) [2,142.2,4,066.0]  | 25.1 (10) [13.2, 47.7]          |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

973.4, 1,345.6], n=141) and Month 12 GMT of 2,280.2 EU/mL [95% CI: 1,929.9, 2,694.2], n=140) as shown in Table 15; while GMTs in participants recruited from Canadian sites decrease between Day 28 and Month 12 after 1-dose V920 (Table 16: Day 28 GMT of 2,058.4 EU/ml [95% CI: 1,367.2, 3,099.2] for n=20 subjects and Month 12 GMT of 1,439.1 EU/ml [95% CI: 932.1, 2,222.0] for n=19 subjects).

Table 15: Summary of Geometric Mean Titers (GP-ELISA Per-Protocol Immunogenicity Population) (Cohort 1 to Cohort 5) (Burkina Faso and Senegal)

| Assay Time Point       | V920 1 Dose* (N-14I) GMT(n) [95%C1]                  | V920 2 Dos (N-40) GMT(n） [95%C1]                                                                       | Pooled V920 (N-181) GMT(n) [95%CI]                                                                                                            | Placcbos (N=44) GMT (n) [95%C1]                                                                                            |
|------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| GP-ELISA               |                                                      |                                                                                                        |                                                                                                                                               |                                                                                                                            |
| Baseline Day 28 Day 56 | 35.1 (140) [29.2, 42.2] 1.144.5(141) [973.4,1,345.6] | 40.6(40) [28.8, 57.2] 1,191.8 (40) [879.4, 1,615.1] 1,469.0 (40) 8,416.0 (40) 2,664.7 (40) 2.264.4(40) | (081)096 [30.9, 42.6] 1.154.8(181) [1,0013,1,331.8] 1,469.0 (40) [1,122.3, 1,923.0] 8,416.0 (40) 2,028.0(181) [1,760.0, 2,336.9] 2.276.7(180) | 29.8 (44) [21.5,41.3] 30.1 (43) [22.4, 40.3] 32.8 (10) [19.2, 56.3] 40.3 (10) [23.8, 68.4] 25.0 (43) [18.7, 33.3] 25.6(43) |
| Day 84                 | 1,876.9(141) [L,600.2.2.201.4]                       | [1,122.3, 1,923.0] [6,461.9, 10,961.1] [1,975.2.3,594.9]                                               | [6,461.9, 10,961.1]                                                                                                                           |                                                                                                                            |
| Month6 Monh12          | 2.280.2(140)                                         |                                                                                                        |                                                                                                                                               |                                                                                                                            |
| Month 12               | [1.929.9, 2.694.2]                                   | [1,657.3,3.093.9]                                                                                      | [1.965.9.2.636.7]                                                                                                                             | [18.9,34.6]                                                                                                                |

Nnumber of participants with serology data at one or more timepoints according to the intervention to which they were randomized. n-numberof participants contributing to the analysis,

CI=confidkence interval; GP-ELISA=ani-glycoprotein human enzyme-linked immunosorbent assay (EU/mL): GMT=geometnic mcan titer.

*V920 1 DoseV920 1 Dose Trcatment Group: Cohort 1 Adults CD4≥500 1 dose.Cohort 2 Adults CD4 &gt;350 and ~500 1 dosc. Cohort 3 Adults CD4 ≥200 and ≤350 1 dose. Cohort 4 Adolescents CD4&gt;2001 dose.

Cohorts 1-5 Adults and adolescents CD4&gt;200 1 or 2 dose.

V920 2 Dose=V920 2Dose Treatment Group: Cohon 5 Adults and adolescents CD4≥200 2 dose.

Table 16: Summary of Geometric Mean Titers (GP-ELISA Per-Protocol Immunogenicity Population) (Cohort 1 to Cohort 5) (Canada)

| Assay Timc Point   | V920 1 Dosea (N=20) GMT (m) [95% CI]   | Poolcd V920c (N=20) GMT (n) [95% CI]   | Placcboc (N=5) GMT (n) [95% CI]   |
|--------------------|----------------------------------------|----------------------------------------|-----------------------------------|
| GP-ELISA           |                                        |                                        |                                   |
| Basclinc           | 21.7 (18) [17.0, 27.7]                 | 21.7 (18) [17.0, 27.7]                 | 18.1 (5) [11.4, 28.7]             |
| Day 28             | 2,058.4 (20) [1,367.2,3,099.2]         | 2,058.4 (20) [1,367.2,3,099.2]         | 18.1 (5) [8.0, 40.9]              |
| Month 6            | 1,622.5 (20) [1,133.2,2,323.1]         | 1,622.5 (20) [1,133.2, 2,323.1]        | 18.1 (5) [8.8, 37.0]              |
| Month 12           | 1,439.1 (19) [932.1,2,222.0]           | 1,439.1 (19) [932.1,2,222.0]           | 18.1 (4) [7.0, 46.5]              |

## Summary of GP-ELISA Geometric Mean Fold Increase

As shown in Table 17, relatively to GP-ELISA GMFI, the following is noted:

- For the 1-dose V920 group (Cohorts 1 to 4 combined), GP-ELISA titres increased by 36.7-fold (95% CI: 30.4-44.2 / n=158) from baseline to Day 28 and remained elevated with trends towards increases in GMFIs at Month 6 (GMFI 55.5 [95% CI: 45.3, 67.9] for n=158) and at Month 12 (GMFI 64.5 [95% CI: 52.4, 79.5] for n=157) as compared to baseline.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- For the 2-dose V920 group (Cohort 5), GP-ELISA titres from baseline peaked at Day 84 (approximately 207-fold). The GMFIs for the 2-dose V920 group were generally comparable with the 1-dose V920 group (Cohorts 1 to 4 combined) at Months 6 and 12.
- No fold increase in GP-ELISA titres was observed at any timepoint in the pooled placebo group (Cohorts 1 to 5 combined).

Table 17: Summary of Geometric Mean Fold Increase (GP-ELISA Per-Protocol Immunogenicity Population - Cohort 1 to Cohort 5)

| Away Time Point   | V920 1 Dose (N-161) GMFI (n) [9596 C1]   | V920 2 Dose (N=40) GMFI (n) [95% C1]   | Pooled V920* (N-201) GMFI (m) [95% C1]   | Placebo* (N=49) GMFI (n) [95% C1]   |
|-------------------|------------------------------------------|----------------------------------------|------------------------------------------|-------------------------------------|
| GP-ELISA          |                                          |                                        |                                          |                                     |
| Day 28            | 36.7(158) [30.4, 44.2]                   | 29.4 (40) [20.3,42.5]                  | 35.1(198) [29.7,41.4]                    | 1.0 (48) [0.7, 1.4]                 |
| Day 56b           |                                          | 36.2(40)                               | 36.2 (40)                                | 0.8 (10)                            |
| Day 84b           |                                          | [24.8, 52.9] 207.4 (40) [143.0, 300.6] | [24.8,52.9] 207.4 (40) [143.0. 300.6]    | [0.4, 1.6] 0.9 (10)                 |
| Month 6           | 55.5 (158) [45.3, 67.9]                  | 65.7 (40) [44.0, 98.1]                 | 57.4 (198) [47.9, 68.7]                  | [0.4, 2.0] 0.8 (48) [0.6, 1.2]      |
| Month 12          | 64.5 (157)                               | 55.8(40)                               | 62.7 (197) [52.0, 75.5]                  | 0.9(47) [0.6, 1.3]                  |
| Monh 12           | [52.4, 79.5]                             | [36.9, 84.4]                           |                                          |                                     |

Nnumber of participanis with serology data at one or more timepoints according to the intervention to which they were randomized.

n=number of participants contributing to the analysis. Participant must have scrology data at baseline and timepoint.

GMFlgeometric mcan fold incrvasc; CI=confidence intcrval; GP-ELISA=anti-glycoprotcin human cnzyme-linked immunosorbent assay (EU/mL),

= V920 1 Dose V920 1 Dose Treatment Group: Cohort 1 Adults CD4500 1 dose. Cohort 2 Adults CD4 &gt;350 and &lt;500 1 dosc. Cohort 3 Adults CD4 ≥200 and ≤350 1 dose. Cohort 4 Adolescenls CD4&gt;200 1 dose.

b V920 2 Dose=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4&gt;200 2 dost.

Cohorts 1-5 Adults and adolescents CD4&gt;200 1 or 2 dosc.

## Summary of GP-ELISA Seroresponse Rates

Most ( ≥ 98%) participants in the pooled V920 group (Cohorts 1 to 5 combined) had a seroresponse ( ≥ 2fold increase from baseline and ≥ 200 EU/mL, or ≥ 4-fold increase from baseline) at any time postvaccination. Few (&lt;11%) participants who received placebo had a seroresponse by either definition.

After Vaccination 2 in the 2-dose V920 group (Cohort 5), all participants had seroresponse by either definition at Day 84, which remained through Month 6. At Month 12, the proportions of participants in the 2-dose V920 group with a seroresponse by either definition were generally comparable with the proportion at Day 28 and with the 1-dose V920 group (Cohorts 1 to 4 combined) at Month 12.

## Immunogenicity Results - PRNT

## Summary of PRNT Geometric Mean Titers

The PRNT GMTs for the 1-dose V920 (Cohorts 1 to 4 combined) and the 2-dose V920 (Cohort 5) groups are shown in Table 18.

## Data indicate that:

- GMTs increased post-vaccination and remained elevated through Month 12. Similarly to what observed for GP-ELISA GMTs, a trend towards increase in PRNT GMTs at Month 12 as compared to Day 28 GMT in the V920 1-dose group is noted.
- Post-vaccination GMTs were higher than those of the pooled placebo group at all timepoints after baseline.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- The PRNT GMTs of the 2-dose V920 group (Cohort 5) peaked at Day 84 and decreased at Months 6 and 12. The 2-dose V920 group had generally comparable concentrations as the 1-dose V920 group (Cohorts 1 to 4 combined) at Month 12.

## Table 18: Summary of Geometric Mean Titers (PRNT Per-Protocol Immunogenicity Population Cohort 1 to Cohort 5)

| Assay Time Point   | V920 1 Dosca (N=161) GMT (n) [95% C1]   | V920 2 Doseb (N=40) GMT (n) [95% C1]            | Pooled V920c (N=201) GMT (n) [95% CI]              | Placcboc (N=49) GMT (n) [95% CI]    |
|--------------------|-----------------------------------------|-------------------------------------------------|----------------------------------------------------|-------------------------------------|
| PRNT               |                                         |                                                 |                                                    |                                     |
| Baseline           | 17.7 (161) [17.4, 18.1]                 | 17.5 (40) [16.7, 18.3] 119.8 (40) [88.9, 161.5] | 17.7 (201) [17.4, 18.1] 206.9 (201) [180.4, 237.3] | 17.5 (49) [16.8, 18.2] 17.5 (48)    |
| Day 28             | 237.0 (161) [204.2,275.0]               |                                                 |                                                    |                                     |
| Day 56b            |                                         | 166.0 (40)                                      | 166.0 (40)                                         | [13.3, 23.0] 17.5 (10)              |
| Day 84b            |                                         | [134.4, 205.1] 1,516.2 (40) [1,250.0, 1,838.9]  | [134.4, 205.1] 1,516.2 (40) [1,250.0, 1,838.9]     | [11.5, 26.7] 17.5 (10) [11.9, 25.7] |
| Month 6            | 250.2 (161) [217.8, 287.6]              | 415.1 (40) [314.0, 548.7]                       | 276.8 (201) [243.8, 314.2]                         | 17.5 (48) [13.6, 22.6]              |
| Month 12           | 361.4 (159) [314.4, 415.3]              | 434.2 (40) [329.1, 573.0]                       | 375.0 (199) [331.1, 424.6]                         | 18.7 (47) [14.5, 24.1]              |

N=number of participants with serology data at one or more timepoints according to the intervention towhich theywere randomized.

n=number of participants contributing to the analysis.

Cl=confidence interval;PRNT=plaquc reduction neutralization test; GMT=gcomctric mcan titer.

a V920 1 Dose=V9201 Dose Treatment Group: Cohort 1 Adults CD4≥5001 dose.Cohort 2Adults CD4&gt;350 and&lt;5001 dose.Cohort 3 Adults CD4≥200 and ≤3501 dosc. Cohort 4 Adolcscents CD4&gt;2001 dosc.

b V920 2 Dosc=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4&gt;200 2 dose.

e Cohorts 1-5 Adults and adolescents CD4&gt;200 1 or 2 dose.

In the CSR, PRNT GMTs are presented separately by cohort and by subgroup (adults, adolescents, female, male, GPELISA baseline levels (≥200 EU/mL or &lt;200 EU/mL), African sites participants, Canadian sites participants).

In adults PRNT GMTs increased from 17.8 (N=121) at baseline to 223.8 (N=121) at Month 1, 237.5 (N=121) at Month 6 and 338.0 (N=119) at Month 12. In adolescents PRNT GMTs rose from 17.5 (N=40) at baseline to 281.9 (N=40) at Month 1, 293.0 (N=40) at Month 6 and 440.9 (N=40) at Month 12.

The number of subjects in these analyses is limited to conclude on differences across cohort/subgroups, trends similar to those described in 'Summary of GP-ELISA Geometric Mean Titres' are however noted.

## Summary of PRNT Geometric Mean Fold Increase

As shown in Table 19, relatively to PRNT GMFI, the following is noted:

- For the 1-dose V920 group (Cohorts 1 to 4 combined), PRNT titres increased by 13.4-fold (95% CI: 11.5-15.5 / n=161) from baseline to Day 28 and remained elevated with trends towards increases in GMFIs at Month 12 (GMFI 20.4 [95% CI: 17.7, 23.5] for n=159) as compared to baseline.
- For the 2-dose V920 group (Cohort 5), PRNT titres from baseline peaked at Day 84 (86.6-fold). The GMFI for the 2-dose V920 group was generally comparable with the 1-dose V920 group (Cohorts 1 to 4 combined) at Month 12.
- No fold increase in PRNT titres was observed at any timepoint in the pooled placebo group (Cohorts 1 to 5 combined).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 19: Summary of Geometric Mean Fold Increase (PRNT Per-Protocol Immunogenicity Population - Cohort 1 to Cohort 5)

| Assay Time Point   | V920 1 Dose* (N=161) GMFI(n) [95%C]]   | V920 2 Dose (N=40) GMFI (n) [95%C1]   | Pooled V920F (N=201) GMFI(n) [95% C1]   | Placebos (N=49) GMFI() [95%C1]   |
|--------------------|----------------------------------------|---------------------------------------|-----------------------------------------|----------------------------------|
| PRNT               |                                        |                                       |                                         |                                  |
| Day 28             | 13.4(161) [11.5.15.5]                  | 6.8(40) [5.0, 9.3]                    | 11.7 (201) [10.2, 13.4]                 | 1.0(48) [0.8,1.3]                |
| Day 56a            |                                        | 9.5 (40)                              | 9.5 (40)                                | 1.0(10)                          |
| Day 84#            |                                        | [7.7,11.7] 86.6 (40)                  | [7.7, 11.7] 86.6 (40)                   | [0.7, 1.5] 1.0(10)               |
| Month6             | 14.1(161)                              | [71.4,105.1] 23.7 (40)                | [71.4,105.1] 15.6 (201) [13.7, 17.8]    | [0.7,1.5] 1.0(48)                |
| Month 12           | [12.2,16.3] 20.4(159)                  | [17.8,31.5] 24.8(40)                  | 21.2(199)                               | [0.8,1.3] 1.1(47)                |
| Month 12           | [17.7.23.5]                            | [18.7,32.9]                           | [18.7,24.1]                             | [0.8,1.4]                        |

N=number of participants with serology data at one or more timcpoints according to the intervention to which they wcre randomized.

n=number of participants contnbuting to the analysis.Participant must have serology data at baseline and timepoint.

*V920 1 Dose=V920 1 Dose Treatment Group: Cohort 1 Adults CD4&gt;500 1 dose.Cohort 2 Adults CD4 &gt;350 and &lt;500 1 dosc. Cohort 3 Adults CD4 &gt;200 and ≤350 1 dose. Cohort 4Adolescents CD4&gt;200 1 dose.

GMFlgeomctric mean fold increase; CIconfidence interval; PR NTplaque reduction neutralization test.

V920 2 Dose=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4&gt;200 2 dose.

Cohorts 1-5 Adults and adolesccnts CD4≥200 1 or 2 dose.

## Summary of PRNT Seroresponse Rates

Most (98.0%) participants in the pooled V920 group (Cohorts 1 to 5 combined) had a seroresponse defined as ≥ 4-fold increase from baseline at any time post-vaccination (Table 14.2-87). Few (2.1%) participants who received placebo had a seroresponse by this definition.

After Vaccination 2 in the 2-dose V920 group (Cohort 5), all participants had a seroresponse defined as ≥ 4-fold increase from baseline at Day 84, which remained elevated through Month 12.

## 6.3. Discussion

V920-015 is a Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of 1 or 2 doses of the V920 (rVSVΔG -ZEBOV-GP) Ebola Virus Vaccine Candidate in adolescents and adults 13 to 70 years of age (inclusive) living with HIV.

Study V920-015 has been conducted in Canada, Burkina Faso and Senegal (non-endemic for EBOV) from November 2017 (first participant first visit 01/11/2017) to March 2023 (last participant last visit 03/03/2023).

## Methods

The overall trial design (including its amendments) is deemed acceptable.

Briefly, the study was designed to enrol sequentially 5 study cohorts based on CD4+ T cell counts and age, with 50 participants planned to be enrolled per cohort to be randomly assigned to receive 1 dose of V920 or placebo in a 4:1 ratio. In Cohort 5, adolescent and adult participants were to be randomly assigned to receive 1 dose of V920 or placebo in a 4:1 ratio on Day 0, followed by booster vaccination at Day 56 (matching vaccine).

The intended study populations were non-pregnant adolescents and adults living with HIV on antiretroviral therapy with undetectable HIV loads and CD4+ T cell counts above 200 cell/mm3, which is deemed appropriate to study safety and immunogenicity of ERVEBO in PLwHIV that have a controlled HIV infection and are not immunocompromised based on CD4+ T cell counts. In addition, participants with

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

history of infection with a filovirus or VSV and that had participated in a filovirus vaccine study or received a VSV-vectored vaccine were excluded.

The primary immunogenicity objectives of the MAH were to demonstrate that in adolescent and adult living with HIV (Cohorts 1 to 5 combined) V920 is superior to placebo for the antibody response (GPELISA GMT) on Day 28 (after administration of 1 dose) and for Cohort 5 on Day 84 (equivalent to 28 days after administration of the second dose of vaccine). Secondary immunogenicity objectives included descriptive analyses of the humoral immune responses (determined by GP-ELISA and PRNT assays) at different time-points through 1-year post-vaccination. Descriptive immunogenicity results (GMTs, GMFIs, seroresponse) were provided overall and by subgroup to explore the impact of CD4+ T cell counts, age, sex, baseline GP-ELISA, country (Africa and ex-Africa) on immunogenicity results.

Objectives and endpoints related to clinical immune responses are endorsed. Applied methodologies to assess post-vaccination immune responses (GPELISA and rVSVΔG -ZEBOV-GP PRNT) and applied definitions of seroresponse appear aligned with those of previous clinical studies from MAA and EoI (EMEA/H/C/004554/II/0025).

In study V920015, 3 different V920 Drug Product Lots were used, all had a potency ≥2 x 10E7 pfu/mL . Data on distribution by cohort/country were not provided. This is a limitation given the differences in potency of the different lots, ranging from 5.4 x 10E7 pfu/mL to 3.0 x 10E8 pfu/mL.

## Results

In total, 251 participants were randomized and a total of 250 participants in Cohorts 1 to 5 were vaccinated (201 in the pooled V920 group, 49 in the pooled placebo group) and included in the immunogenicity and safety populations.

Overall demographic characteristics (combined cohorts) show that the majority of participants had a baseline GPELISA &lt;200 EU/mL (91.6%). There were 52.2% participants with a CD4+ T cell count ≥500 cells/mm3 (remaining participants were evenly distributed among participants with CD4 T cell counts 350500 cells/mm3 and participants with CD4 T cell counts ≥200 to ≤350 cells/mm3). Age ranges were comparable between arms, with 25.9% adolescent participants and most recruited adults aged 18-49 years (55% of total recruit ed adults) and only approximately 10% of recruited adults aged ≥60 years. Similar proportions of male and female were recruitment, with some imbalance between arms (higher proportion of V920 vaccinated male participants compared to placebo and lower proportion of V920 vaccinated female participants compared with placebo). Notably, the majority of the participants were randomized at the site in Burkina Faso (152/251; 60.6%), 73/251 (29.1%) were randomized at the site in Senegal and 26/251 (10.4%) in Canada. This is different from what originally planned per protocol (i.e. ~100 subjects from Canadian sites and of ~150 subjects from African sites planned per protocol). Based on the demographic characteristics described per cohort, 25/26 participants recruited in Canada were randomized in Cohort 1 (20/25 vaccinated with V920) and only 1/26 was randomized in Cohort 2 and V920 vaccinated. No adults were randomized for Cohort 3 and 5 and no adolescents were randomized for Cohort 4 and 5 in Canadian sites.

When considering the characteristics of participants of cohort 4 (Adolescents CD4+ T cell counts ≥200 cells/mm3, 1 Dose) and of cohort 5 (Adults and Adolescents CD4+ T cell counts ≥200 cells/mm3, 2 Dose), it is noted that the majority had a CD4 T cell counts ≥500 cells/mm3 (43/50 (86%) in cohort 4 and 37/50 (74%) in cohort 5).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Immune responses after 1 dose of V920

The GP-ELISA and PRNT results obtained within study V920-015 and expressed in GMTs, GMFIs, seroresponse rates (different definitions) collectively show that administration of a single dose of V920 results in sustained binding and neutralizing antibody responses up to Month 12 in adolescents and adults living with HIV on antiretroviral therapy with undetectable HIV loads and CD4+ T cell counts above 200 cell/mm3.

In Cohorts 1 to 5 combined, Day 28 GP-ELISA GMTs were significantly superior as compared to levels detected in placebo-administered participants. GP-ELISA and PRNT GMTs remained elevated and higher than those of the pooled placebo group through Month 12 after a single dose of V920.

An unexpected trend of an increase in GP-ELISA GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the combined 1-dose cohorts is noted (also reflected in terms of GP-ELISA GMFIs results). Similarly, a trend towards an increase in PRNT GMT at Month 12 as compared to Day 28 GMT after 1 dose of V920 is noted (also reflected in terms of PRNT GMFIs results).

Indeed, based on the GP-ELISA GMTs data submitted:

- Stratified by cohort, it appears that for cohort 1 (adults with CD4 T cell counts ≥500 cells/mm3) there was no notable trend towards an increase in GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the V920 1-dose, while for cohort 2 (adults with CD4 T cell counts ranging from 350500 cells/mm3) and for cohort 3 (adults with CD4 T cell counts ranging from ≥200 to ≤350 cells/mm3) increases in GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the V920 1-dose group are marked. In the adolescents of cohort 4, a marked increase in GMTs at Month 12 as compared to Day 28 GMT in the V920 is noted.
- Stratified by continent, it appears that Day 28 GMTs were comparatively higher for the V920 vaccinated participants of the Canadian sites versus participants of African sites; and that in vaccinated participants of African site there was a notable increase in GP-ELISA GMTs between Day 28 and Month 12, while GMTs decreased between Day 28 and Month 12 in vaccinated participants of Canadian sites.

Concerning the observed trend with increases over time in binding and neutralizing antibody responses, the MAH speculates that this might be related to the maturation of the immune response, which can result in a gradual increase or sustained elevation of antibody titres months after vaccination, even in the absence of additional antigen exposure. These unexpected trends in the evolution of antibody levels were also notable in other clinical studies, but they appear more pronounced in study V920-015. The MAH did not discuss whether differences in CD4+ T cell counts in the different cohorts and/or differences in recruitment country and/or differences in the administered lots (potency ranging from 5.4 x 10E7 pfu/mL to 3.0 x 10E8 pfu/mL) might have contributed to the observed increases over time of the measured binding and neutralizing antibody.

When comparing GP-ELISA GMTs in V920 vaccinated adolescents versus adults, a trend towards higher GMTs in adolescents is noted, which is consistent with data from the PREVAC V920-016 study discussed within the EoI type II variation procedure (EMEA/H/C/004554/II/0025).

Concerning humoral responses stratified by baseline GP-ELISA GMTs, only n=11 participants V920 vaccinated had a baseline GPELISA ≥200 EU/mL , analysis is therefore not possible. Concerning humoral responses stratified by sex, trends towards higher humoral responses in females are noted, this being consistent with stratified data from the PREVAC V920-016 study discussed within the EoI type II variation procedure (EMEA/H/C/004554/II/0025), although differences in immune responses between sex were less marked in study V920-015.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Immune responses after 2 doses of V920

In participants of cohort 5, administration of a 2 nd  dose of V920 eight weeks after the primary dose resulted in a boost of binding and neutralizing antibody responses at Day 84 (28 days after the second dose) and antibody levels gradually decreased to comparable concentrations as those measured for the 1-dose V920 group (Cohorts 1 to 4 combined) at Month 12. These results are consistent with data of the PREVAC V920-016 study discussed within the EoI type II variation procedure

(EMEA/H/C/004554/II/0025). However, it is noted that GP-ELISA GMTs measured in Study 015 are comparatively higher than those measured in PREVAC following 2 doses of V920 (with same timing of 2nd dose administration and of sampling post dose 2).

## Conclusion

V920 induces GP-specific binding and neutralizing antibody as observed at Day 28 post-vaccination in adolescent and adults living with a controlled HIV infection (defined as individuals on antiretroviral therapy with undetectable HIV loads and CD4+ T cell counts above 200 cell/mm3). At 1-year postvaccination, Ab levels are still higher than pre-vaccination.

Administration of a second dose of V920 56 days after the primary dose results in a transient boost in binding and neutralizing antibody responses, which declined at Month 12 to levels comparable to those detected after a single primary dose. Need and appropriate timing of administration of a booster dose of V920 remains currently undetermined.

In the absence of ICP, the clinical relevance of those immunogenicity results is unknown.

## 7. Clinical Safety aspects

## 7.1. Methods - analysis of data submitted

Adolescents and adults 13 to 70 years of age (inclusive) living with HIV received either 1 or 2 doses of V920 or placebo and were followed for safety through 1 year after vaccination (1 year after first vaccination for those in the 2-dose group).

Table 20. Summary of Clinical Safety Study V920-015

| Study Number(Status) [CTD Location] Numberof Study Sites (Regions)                                                                          | Design (Indication)                                                                                                                                                                            | Number of Participants by Intervention Group                                                                                                                                                                                                                                                                                                                                                         | Study Population (N)                                                                                                                        | PrimarySafetyEndpoints                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| V920-015(completed) [Ref. 5.3.5.1: P015V920] 4 centers in3countries (Canada,Burkina Faso, and Senegal)                                      | Phase 2,randomized, double-blind,placebo- controlled,parallel-group study Adults and adolescents living with HIV who were 13 to 70 (inclusive) years of age Duration:12 months postvaccination | Cohorts 1 to 4(1 dose [Day 0]): V920≥2 x 10′ pfu:162 randomized,161vaccinated, discontinued study 160 completed study,1 Placebo:39randomized,39 vaccinated,37completed study,2 discontinued study Cohort 5(2 doses Vaccination 2on Day 561): [Vaccination 1 onDay 0: V920 ≥2 x10 pfu (per dose): 40 randomized, vaccinated,and completed study Placebo:10 randomized, vaccinated,and completed study | Cohorts 1 to5: Sex:121Males/130 Females 44 years (13 to 70 years) Overall median age (Range):                                               | ·Solicitedlocal and systemic AEs for 14 days after each vaccination Fever, arthritis, arthralgia, rash,and blisters/vesicular lesions for 42 days after eachvaccination Unsolicited AEsfor42days after eachvaccination Vaccine-related SAEs through to Day 365 Changes in vital signs (eg. blood pressure, heart rate, respiratory rate,and temperature) Changes in clinical laboratory values |
| AE=adverse event;CTD=common technical document;HIV=human immunodeficiency virus; N=number;pfu=plaque-forming unit;SAE=serious adverse event | AE=adverse event;CTD=common technical document;HIV=human immunodeficiency virus; N=number;pfu=plaque-forming unit;SAE=serious adverse event                                                    | AE=adverse event;CTD=common technical document;HIV=human immunodeficiency virus; N=number;pfu=plaque-forming unit;SAE=serious adverse event                                                                                                                                                                                                                                                          | AE=adverse event;CTD=common technical document;HIV=human immunodeficiency virus; N=number;pfu=plaque-forming unit;SAE=serious adverse event | AE=adverse event;CTD=common technical document;HIV=human immunodeficiency virus; N=number;pfu=plaque-forming unit;SAE=serious adverse event                                                                                                                                                                                                                                                    |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 7.1.1. Overall Extent of Exposure

Safety analyses were based on the APaT population, which included randomized participants who received at least 1 dose of study intervention (V920 or placebo). A total of 250 participants in Cohorts 1 to 5 (201 in the pooled V920 group, 49 in the pooled placebo group) were included in the safety population as follows:

- -1 dose of V920 (Cohorts 1 to 4 combined): 161 participants
- -1 dose of placebo (Cohorts 1 to 4 combined): 39 participants
- -2 doses of V920 (Cohort 5): 40 participants
- -2 doses of placebo (Cohort 5): 10 participants

## Details of the cohorts:

- -Cohort 1 (CD4 ≥ 500 cells/mm3): 51 adults (41 vaccinated with V920, 10 with placebo)
- -Cohort 2 (CD4 &gt;350 to &lt;500 cells/mm3): 50 adults (40 vaccinated with V920, 10 with placebo)
- -Cohort 3 (CD4 ≥ 200 cells/mm3 and ≤ 350 cells/mm3): 50 adults (41 vaccinated with V920, 9 with placebo)
- -Cohort 4 (CD4 ≥ 200 cells/mm3): 50 adolescents (40 vaccinated with V920, 10 with placebo)
- -Cohort 5 (CD4 ≥ 200 cells/mm3): 35 adults (28 vaccinated with V920, 7 with placebo)
- -Cohort 5 (CD4 ≥ 200 cells/mm3): 15 adolescents (12 vaccinated with V920, 3 with placebo)

## 7.1.2. Demographic and Other Characteristics of Study Population

The majority of the overall participants in all 5 cohorts were randomized at the site in Burkina Faso (60.6%) (Senegal: 29.1%, Canada: 10.4%), had a baseline GP-ELISA &lt;200 EU/mL (91.6%), or had CD4 ≥ 500 cells/mm3  (52.2%).  Demographic  characteristics  were  generally  comparable  across  study  intervention groups (for age, race, BMI…). However, there was a higher proportion of male participants who received V920 (50.5%) compared with placebo (38.8%), and a lower proportion of females who received V920 (49.5%) compared with placebo (61.2%).

## 7.2. Results

Table  21.  Adverse  Event  Summary  (All  Participants  as  Treated  -  Vaccination  to  42  Days Postvaccination) (Cohort 1 to Cohort 5)

|                                           | V9201Doseb   | V9201Doseb   | V9202Dosec   | V9202Dosec   | PooledV920d   | PooledV920d   | Placebod   | Placebod   |
|-------------------------------------------|--------------|--------------|--------------|--------------|---------------|---------------|------------|------------|
|                                           | n            | (%)          | n            | (%)          | n             | (%)           | n          | (%)        |
| Participants in population with follow-up | 161          |              | 40           |              | 201           |               | 49         |            |
| withone ormoreadverseevents               | 149          | (92.5)       | 39           | (97.5)       | 188           | (93.5)        | 37         | (75.5)     |
| injection-site                            | 105          | (65.2)       | 30           | (75.0)       | 135           | (67.2)        | 14         | (28.6)     |
| non-injection-site                        | 136          | (84.5)       | 39           | (97.5)       | 175           | (87.1)        | 35         | (71.4)     |
| withnoadverseevent                        | 12           | (7.5)        | 1            | (2.5)        | 13            | (6.5)         | 12         | (24.5)     |
| withvaccine-relatedadverse events         | 136          | (84.5)       | 36           | (90.0)       | 172           | (85.6)        | 22         | (44.9)     |
| injection-site                            | 105          | (65.2)       | 30           | (75.0)       | 135           | (67.2)        | 14         | (28.6)     |
| non-injection-site                        | 93           | (57.8)       | 15           | (37.5)       | 108           | (53.7)        | 17         | (34.7)     |
| withserious adverseevents                 | 1            | (0.6)        | 0            | (0.0)        | 1             | (0.5)         | 0          | (0.0)      |
| withseriousvaccine-relatedaadverseevents  | 0            | (0.0)        | 0            | (0.0)        | 0             | (0.0)         | 0          | (0.0)      |
| whodied                                   | 0            | (0.0)        | 0            | (0.0)        | 0             | (0.0)         | 0          | (0.0)      |
| whodiedduetoavaccine-relatedaadverseevent | 0            | (0.0)        | 0            | (0.0)        | 0             | (0.0)         | 0          | (0.0)      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 22. Adverse Event Summary (All Participants as Treated - Second Vaccination to 42 Days Postvaccination 2) (Cohort 5 Adults and Adolescents CD4 ≥ 200, 2 Dose)

|                                                                                                                           | V920   | V920   | Placebo   | Placebo   |
|---------------------------------------------------------------------------------------------------------------------------|--------|--------|-----------|-----------|
|                                                                                                                           | n      | (%)    | n         | (%)       |
| Participantsinpopulationwithfollow-up                                                                                     | 40     |        | 10        |           |
| with one ormore adverseevents                                                                                             | 29     | (72.5) | 7         | (70.0)    |
| injection-site                                                                                                            | 21     | (52.5) | 1         | (10.0)    |
| non-injection-site                                                                                                        | 22     | (55.0) | 7         | (70.0)    |
| withnoadverseevent                                                                                                        | 11     | (27.5) | 3         | (30.0)    |
| withvaccine-relatedadverseevents                                                                                          | 24     | (60.0) | 6         | (60.0)    |
| injection-site                                                                                                            | 21     | (52.5) | 1         | (10.0)    |
| non-injection-site                                                                                                        | 8      | (20.0) | 5         | (50.0)    |
| withserious adverseevents                                                                                                 | 0      | (0.0)  | 1         | (10.0)    |
| withseriousvaccine-relatedaadverseevents                                                                                  | 0      | (0.0)  | 0         | (0.0)     |
| who died                                                                                                                  | 0      | (0.0)  | 0         | (0.0)     |
| whodiedduetoavaccine-relatedaadverseevent                                                                                 | 0      | (0.0)  | 0         | (0.0)     |
| aDetermined by the investigator to berelated to the vaccine. MedDRA version 27.0 was used in the reporting of this study. |        |        |           |           |

Table  23.  Adverse  Event  Summary  (All  Participants  as  Treated  -  Vaccination  to  1  Year Postvaccination) (Cohort 1 to Cohort 5)

|                                           | V920 1 Doseb   | V920 1 Doseb   | V9202Dosec   | V9202Dosec   | Pooled V920d   | Pooled V920d   | Placebod   | Placebod   |
|-------------------------------------------|----------------|----------------|--------------|--------------|----------------|----------------|------------|------------|
|                                           | n              | (%)            | n            | (%)          |                | (%)            |            | (%)        |
| Participants in population with follow-up | 161            |                | 40           |              | 201            |                | 49         |            |
| withoneormoreadverseevents                | 149            | (92.5)         | 39           | (97.5)       | 188            | (93.5)         | 38         | (77.6)     |
| injection-site                            | 105            | (65.2)         | 30           | (75.0)       | 135            | (67.2)         | 14         | (28.6)     |
| non-injection-site                        | 136            | (84.5)         | 39           | (97.5)       | 175            | (87.1)         | 36         | (73.5)     |
| withnoadverseevent                        | 12             | (7.5)          | 1            | (2.5)        | 13             | (6.5)          | 11         | (22.4)     |
| withvaccine-relatedadverseevents          | 136            | (84.5)         | 37           | (92.5)       | 173            | (86.1)         | 26         | (53.1)     |
| injection-site                            | 105            | (65.2)         | 30           | (75.0)       | 135            | (67.2)         | 14         | (28.6)     |
| non-injection-site                        | 93             | (57.8)         | 16           | (40.0)       | 109            | (54.2)         | 21         | (42.9)     |
| withseriousadverseevents                  | 3              | (1.9)          | 0            | (0.0)        | 3              | (1.5)          | 2          | (4.1)      |
| withseriousvaccine-relatedaadverseevents  | 0              | (0.0)          | 0            | (0.0)        | 0              | (0.0)          | 0          | (0.0)      |
| who died                                  | 0              | (0.0)          | 0            | (0.0)        | 0              | (0.0)          | 0          | (0.0)      |
| whodiedduetoavaccine-relatedaadverseevent | 0              | (0.0)          | 0            | (0.0)        | 0              | (0.0)          | 0          | (0.0)      |

MedDRAversion 27.0 was usedin thereporting of this study.

The majority of participants in the pooled V920 (93.5%) and pooled placebo (75.5%) groups (Cohorts 1 to 5 combined) experienced ≥ 1 AE within 42 days postvaccination (Vaccination 1 for Cohort 5) (Table 21). The proportions  of  participants  who  had  injection-site  AE  (67.2%),  systemic  AE  (87.1%),  vaccine-related injection-site AE (67.2%), and vaccine-related systemic AE (53.7%) were higher in the pooled V920 group compared with the pooled placebo group (28.6%, 71.4%, 28.6%, and 34.7% respectively).

Overall, the proportions of participants who had AE within the 42-days postvaccination (after Vaccination 1 for Cohort 5) were generally slightly higher in the 2-dose group (cohort 5 after 1 vaccination) compared to the 1-dose V920 groups (cohorts 1 to 4) (Table 20).

In the 2-dose V920 group (cohort 5), the proportions of participants who had AE within 42-days after the 1 st  vaccination was higher than after the 2 nd  vaccination (Table 22).

The proportions of participants who had AE within 1-year postvaccination were similar to those within 42days postvaccination (Table 23).

SAEs were reported for few participants within 1 year postvaccination (3 in the 1-dose V920 group and 2 in the placebo group) and none of the SAEs were considered to be related to study intervention by the investigator. No participant discontinued study intervention or the study due to an AE or died within 1 year postvaccination.

Per cohort, the proportions of participants who had an AE within the 42-days postvaccination were:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- -Cohort 1 (adults): 97.5% in V920 group versus 80% in placebo;
- -Cohort 2 (adults): 85% in V920 group versus 70% in placebo;
- -Cohort 3 (adults): 92.7% in V920 group versus 66.7% in placebo;
- -Cohort 4 (adolescents): 95% in V920 group versus 80% in placebo;
- -Cohort 5 (adolescents + adults): 97.5% in V920 group versus 80% in placebo.

## 7.2.1. Common Adverse Events

## 7.2.1.1. Solicited Local and Systemic Adverse Events

## Table 24. Participants With Solicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups)  (Local  and Systemic)  (All Participants as Treated  Vaccination to  14  Days Postvaccination) (Cohort 1 to Cohort 5)

|                                           | V9201 Dosea   | V9201 Dosea   | V920 2Doseb   | V920 2Doseb   | Pooled V920c   | Pooled V920c   | Placeboc   | Placeboc   |
|-------------------------------------------|---------------|---------------|---------------|---------------|----------------|----------------|------------|------------|
|                                           | n             | (%)           | n             | (%)           | n              | (%)            | n          | (%)        |
| Participants in population with follow-up | 161           |               | 40            |               | 201            |                | 49         |            |
| withoneormoresolicitedadverseevents       | 142           | (88.2)        | 35            | (87.5)        | 177            | (88.1)         | 30         | (61.2)     |
| withnosolicitedadverseevents              | 19            | (11.8)        | 5             | (12.5)        | 24             | (11.9)         | 19         | (38.8)     |
| Solicitedlocaladverseevent                | 104           | (64.6)        | 30            | (75.0)        | 134            | (66.7)         | 14         | (28.6)     |
| Injection site erythema                   | 9             | (5.6)         | 0             | (0.0)         | 9              | (4.5)          | 2          | (4.1)      |
| Injection site pain                       | 100           | (62.1)        | 30            | (75.0)        | 130            | (64.7)         | 12         | (24.5)     |
| Injection site swelling                   | 10            | (6.2)         | 1             | (2.5)         | 11             | (5.5)          | 3          | (6.1)      |
| Solicited systemic adverse event          | 119           | (73.9)        | 32            | (80.0)        | 151            | (75.1)         | 26         | (53.1)     |
| Abdominal pain                            | 17            | (10.6)        | 8             | (20.0)        | 25             | (12.4)         | 4          | (8.2)      |
| Arthralgia                                | 40            | (24.8)        | 10            | (25.0)        | 50             | (24.9)         | 4          | (8.2)      |
| Blister                                   | 2             | (1.2)         | 0             | (0.0)         | 2              | (1.0)          | 0          | (0.0)      |
| Chills                                    | 27            | (16.8)        | 6             | (15.0)        | 33             | (16.4)         | 2          | (4.1)      |
| Diarrhoea                                 | 15            | (9.3)         | 2             | (5.0)         | 17             | (8.5)          | 3          | (6.1)      |
| Fatigue                                   | 71            | (44.1)        | 20            | (50.0)        | 91             | (45.3)         | 11         | (22.4)     |
| Feeling hot                               | 36            | (22.4)        | 15            | (37.5)        | 51             | (25.4)         | 7          | (14.3)     |
| Headache                                  | 86            | (53.4)        | 23            | (57.5)        | 109            | (54.2)         | 13         | (26.5)     |
| Hyperhidrosis                             | 19            | (11.8)        | 7             | (17.5)        | 26             | (12.9)         | 2          | (4.1)      |
| Joint swelling                            | 0             | (0.0)         | 0             | (0.0)         | 0              | (0.0)          | 1          | (2.0)      |
| Myalgia                                   | 25            | (15.5)        | 10            | (25.0)        | 35             | (17.4)         | 3          | (6.1)      |
| Nausea                                    | 19            | (11.8)        | 9             | (22.5)        | 28             | (13.9)         | 3          | (6.1)      |
| Pyrexia                                   | 10            | (6.2)         | 1             | (2.5)         | 11             | (5.5)          | 0          | (0.0)      |
| Rash                                      | 6             | (3.7)         | 2             | (5.0)         | 8              | (4.0)          | 5          | (10.2)     |

Everyparticipant iscounted a single timefor each applicablerow and column.

aV920 1 Dose=V920 1 Dose Treatment Group:Cohort 1Adults CD4&gt;5001 dose.Cohort 2 Adults CD4 &gt;350 and&lt;5001 dose.Cohort 3 Adults CD4≥200 and≤350 1 dose. Cohort4AdolescentsCD4≥2001dose.

cCohorts 1-5 Adults and adolescents CD4≥200 1 or 2 dose.For Cohort 5,adverse events are presented for 14 days postvaccination 1.

b V920 2 Dose=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4≥200 2 dose.For Cohort 5, adverse events are presented for 14 days postvaccination 1.

MedDRAversion 27.0 wasused in the reporting of thisstudy.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 25. Participants With Solicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups)  (Local  and  Systemic)  (All  Participants  as  Treated  -  Second  Vaccination  to  14  Days Postvaccination 2) (Cohort 5 Adults and Adolescents CD4 ≥ 200, 2 Dose)

|                                       | V920   | V920   | Placebo   | Placebo   |
|---------------------------------------|--------|--------|-----------|-----------|
|                                       | n      | (%)    | n         | (%)       |
| Participantsinpopulationwithfollow-up | 40     |        | 10        |           |
| withoneormoresolicitedadverseevents   | 25     | (62.5) | 6         | (60.0)    |
| withnosolicitedadverseevents          | 15     | (37.5) | 4         | (40.0)    |
| Solicited local adverse event         | 21     | (52.5) | 1         | (10.0)    |
| Injection site pain                   | 20     | (50.0) | 1         | (10.0)    |
| Injection site swelling               | 1      | (2.5)  | 0         | (0.0)     |
| Solicited systemic adverse event      | 13     | (32.5) | 5         | (50.0)    |
| Abdominal pain                        | 4      | (10.0) | 1         | (10.0)    |
| Arthralgia                            | 3      | (7.5)  | 0         | (0.0)     |
| Blister                               | 1      | (2.5)  | 0         | (0.0)     |
| Chills                                | 1      | (2.5)  | 1         | (10.0)    |
| Diarrhoea                             | 4      | (10.0) | 2         | (20.0)    |
| Fatigue                               | 2      | (5.0)  | 2         | (20.0)    |
| Feeling hot                           | 3      | (7.5)  | 1         | (10.0)    |
| Headache                              | 6      | (15.0) | 1         | (10.0)    |
| Myalgia                               | 0      | (0.0)  | 2         | (20.0)    |
| Nausea                                | 4      | (10.0) | 1         | (10.0)    |
| Pyrexia                               | 1      | (2.5)  | 0         | (0.0)     |
| Rash                                  | 1      | (2.5)  | 0         | (0.0)     |

Every participantis counted a single timefor each applicablerow andcolumn.

Pyrexia was defined as maximum temperature ≥100.4°F (38.0 °C) solicited from vaccination to 14 days postvaccination.

The majority of participants in the pooled V920 (88.1%) and pooled placebo (61.2%) groups (Cohorts 1 to 5 combined) experienced ≥ 1 solicited AE within 14 days postvaccination (Vaccination 1 for Cohort 5) (Table 24). The proportions of participants who had solicited local AE (66.7%) and systemic AE (75.1%) were higher in the pooled V920 group compared with the pooled placebo group (28.6% and 53.1% respectively).

Overall, the proportions of participants who had solicited AE (for both local and systemic AE) within the 14 days postvaccination (after Vaccination 1 for Cohort 5) were generally slightly higher in the 2-dose group (cohort 5 after 1 vaccination) compared to the 1-dose V920 groups (cohorts 1 to 4) (Table 24).

In the 2-dose V920 group (cohort 5), the proportions of participants who had solicited AE within 14 days after the 1 st  vaccination was higher (87.5%) than within 14 days after the 2 nd  (62.5%) (Table 24 and Table 25).

In  the  pooled  V920  group  (Cohorts  1  to  5  combined),  the  reported  solicited  AEs  within  14  days postvaccination (Vaccination 1 for Cohort 5) were (Table 24):

- -Local: injection-site pain (64.7% versus 24.5% in placebo), swelling (5.5% vs. 6.1%, respectively), and erythema (4.5% vs. 4.1%)
- -Systemic:  headache  (54.2%  vs.  26.5%  in  placebo),  fatigue  (45.3%  vs.  22.4%,  respectively), feeling hot (25.4% vs. 14.3%), arthralgia (24.9% vs. 8.2%), myalgia (17.4% vs. 6.1%), chills (16.4% vs. 4.1%), nausea (13.9% vs. 6.1%), hyperhidrosis (12.9% vs. 4.1%), abdominal pain (12.4% vs. 8.2%), diarrhoea (8.5% vs. 6.1%), pyrexia (5.5% vs. 0%), rash (4% vs. 10.2%), and blister (1% vs. 0).

In the pooled V920 group, the majority of the solicited AE within 14 days postvaccination were mild (70.1%) or moderate (15.4%) in intensity. Six participants reported severe solicited AEs:

- -1-dose V920 group (5 participants): 3 chill, 3 fatigue, 2 feeling hot, 2 headache, 2 hyperhidrosis, 1 myalgia, 1 nausea, 2 pyrexia.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- -2-dose V920 group (1 participant after vaccination 1): 1 chill, 1 fatigue, 1 feeling hot, 1 headache, 1 hyperhidrosis, 1 myalgia.

## Related events:

Table 26. Participants With Vaccine-Related Solicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups) (Local and Systemic) (All Participants as Treated - Vaccination to 14 Days Postvaccination) (Cohort 1 to Cohort 5)

|                                                           | V920 1 Dose*   | V920 1 Dose*   | V920 2 Doseb   | V920 2 Doseb   |   Poolcd V920c | Poolcd V920c   | Placeboc   | Placeboc   |
|-----------------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|------------|------------|
|                                                           | n              | (%)            |                | (%)            |             11 | (%)            |            | (%)        |
| Participants in population with follow-up                 | 161            |                | 40             |                |            201 |                | 49         |            |
| with one or more vaccine-relatcd solicited adverse events | 134            | (83.2)         | 35             | (87.5)         |            169 | (84.1)         | 20         | (40.8)     |
| withnovaccine-relatedsolicited adverse events             | 27             | (16.8)         | 5              | (12.5)         |             32 | (15.9)         | 29         | (59.2)     |
| Solicitedlocaladverse event                               | 104            | (64.6)         | 30             | (75.0)         |            134 | (66.7)         | 14         | (28.6)     |
| Injection site erythema                                   | 9              | (5.6)          | 0              | (0.0)          |              9 | (4.5)          | 2          | (4.1)      |
| Injection site pain                                       | 100            | (62.1)         | 30             | (75.0)         |            130 | (64.7)         | 12         | (24.5)     |
| Injection site swelling                                   | 10             | (6.2)          | 1              | (2.5)          |             11 | (5.5)          | 3          | (6.1)      |
| Solicitedsystemicadverse event                            | 86             | (53.4)         | 13             | (32.5)         |             99 | (49.3)         | 12         | (24.5)     |
| Abdominal pain                                            | 9              | (5.6)          | 5              | (12.5)         |             14 | (7.0)          | 1          | (2.0)      |
| Arthralgia                                                | 28             | (17.4)         | 4              | (10.0)         |             32 | (15.9)         | 2          | (4.1)      |
| Blister                                                   | 2              | (1.2)          | 0              | (0.0)          |              2 | (1.0)          | 0          | (0.0)      |
| Chills                                                    | 20             | (12.4)         | 4              | (10.0)         |             24 | (11.9)         | 1          | (2.0)      |
| Diarrhoca                                                 | 6              | (3.7)          | 1              | (2.5)          |              7 | (3.5)          | 1          | (2.0)      |
| Fatigue                                                   | 46             | (28.6)         | 8              | (20.0)         |             54 | (26.9)         | 5          | (10.2)     |
| Fecling hot                                               | 18             | (11.2)         | 7              | (17.5)         |             25 | (12.4)         | 3          | (6.1)      |
| Headache                                                  | 47             | (29.2)         | 8              | (20.0)         |             55 | (27.4)         | 5          | (10.2)     |
| Hyperhidrosis                                             | 10             | (6.2)          | 5              | (12.5)         |             15 | (7.5)          | 2          | (4.1)      |
| Joint swelling                                            | 0              | (0.0)          | 0              | (0.0)          |              0 | (0.0)          | 1          | (2.0)      |
| Myalgia                                                   | 15             | (9.3)          | 5              | (12.5)         |             20 | (10.0)         | 1          | (2.0)      |
| Nausca                                                    | 9              | (5.6)          | 6              | (15.0)         |             15 | (7.5)          | 3          | (6.1)      |
| Pyrexia                                                   | 10             | (6.2)          | 1              | (2.5)          |             11 | (5.5)          | 0          | (0.0)      |

Every participant is counted a single time for cach applicable row and column.

Pyrexiawas defined as maximum temperature≥100.4 °F(38.0°C) solicited from vaccination to 14 days postvaccination.All cascs of pyrexia wcre dctcrmincd by thc investigator to be related.

a V920 1 Dosc=V920 1 Dose Treatment Group: Cohort 1 Adults CD4≥500 1 dosc. Cohort 2 Adults CD4 &gt;350 and &lt;500 1 dosc. Cohort 3 Adults CD4 ≥200 and ≤350 1 dosc. Cohort4 Adolcscents CD4&gt;200 1 dosc.

b V920 2 Dosc=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4≥200 2 dose. For Cohort 5, adverse events are presented for 14 days postvaccination 1. cCohorts 1-5Adults and adolesccnts CD4&gt;200 1 or 2 dosc.For Cohort 5, advcrsc cvents are presented for 14 days postvaccination 1.

McdDRA version 27.0 was used in the reporting of this study.

Up to 14 days after vaccination, all solicited local AE were assessed as related to the vaccine: 66.7% in the pooled V920 versus 28.6% in placebo (table above). The frequencies of the solicited systemic AE assessed as related to the vaccine were 49.3% in the pooled V920 (out of 75.1%) versus 24.5% in placebo (out of 53.1%).

In the 2-dose V920 group (cohort 5), the proportions of participants who had related solicited AE within 14 days after the 1 st  vaccination was higher (87.5%) than within 14 days after the 2 nd  (60%).

In the pooled V920 group (Cohorts 1 to 5 combined), the reported related solicited systemic AEs within 14 days postvaccination (Vaccination 1 for Cohort 5) were (table above): headache (27.4% vs. 10.2% in placebo), fatigue (26.9% vs. 10.2%, respectively), feeling hot (12.4% vs. 6.1%), arthralgia (15.9% vs. 4.1%), myalgia (10% vs. 2%), chills (11.9% vs. 2%), nausea (7.5% vs. 6.1%), hyperhidrosis (7.5% vs. 4.1%), abdominal pain (7% vs. 2%), diarrhoea (3.5% vs. 2%), pyrexia (5.5% vs. 0%), rash (2% vs. 2%), and blister (1% vs. 0). (Of note, all events of pyrexia were assessed as related to the vaccine.)

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 7.2.1.2. Solicited Events Specific to Postvaccination

Table 27. Participants With Solicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups) (Events Specific  to  Postvaccination) (All Participants as Treated - Vaccination to 42 Days Postvaccination) (Cohort 1 to Cohort 5)

|                                           | V9201Dosea   | V9201Dosea   | V920 2Doseb   | V920 2Doseb   | Pooled V920c   | Pooled V920c   | Placeboc   | Placeboc   |
|-------------------------------------------|--------------|--------------|---------------|---------------|----------------|----------------|------------|------------|
|                                           | n            | (%)          | n             | (%)           |                | (%)            | n          | (%)        |
| Participants in population with follow-up | 161          |              | 40            |               | 201            |                | 49         |            |
| withone ormoresolicited adverseevents     | 57           | (35.4)       | 16            | (40.0)        | 73             | (36.3)         | 11         | (22.4)     |
| withnosolicitedadverseevents              | 104          | (64.6)       | 24            | (60.0)        | 128            | (63.7)         | 38         | (77.6)     |
| Solicitedsystemicadverseevent             | 57           | (35.4)       | 16            | (40.0)        | 73             | (36.3)         | 11         | (22.4)     |
| Arthralgia                                | 46           | (28.6)       | 12            | (30.0)        | 58             | (28.9)         | 8          | (16.3)     |
| Blister                                   | 3            | (1.9)        | 0             | (0.0)         | 3              | (1.5)          | 0          | (0.0)      |
| Joint swelling                            | 0            | (0.0)        | 0             | (0.0)         | 0              | (0.0)          | 1          | (2.0)      |
| Pyrexia                                   | 18           | (11.2)       | 3             | (7.5)         | 21             | (10.4)         | 0          | (0.0)      |
| Rash                                      | 9            | (5.6)        | 3             | (7.5)         | 12             | (6.0)          | 5          | (10.2)     |

Everyparticipantiscountedasingletimeforeachapplicablerow andcolumn.

Pyrexia was defined as maximum temperature≥100.4°F(38.0°C) solicitedfrom vaccination to 42 days postvaccination.

aV920 1 Dose=V920 1 Dose Treatment Group: Cohort 1 Adults CD4≥500 1 dose.Cohort 2 Adults CD4 &gt;350 and &lt;500 1 dose.Cohort 3 Adults CD4≥200 and ≤350 1 dose. Cohort4Adolescents CD4&gt;2001dose.

b V920 2 Dose=V920 2 Dose Treatment Group:Cohort 5 Adults and adolescents CD4&gt;200 2 dose.For Cohort 5,adverse events are presented for 42 days postvaccination 1. cCohorts 1-5Adults and adolescents CD4&gt;2001or 2dose.ForCohort 5,adverse events are presented for 42dayspostvaccination 1.

MedDRAversion27.0wasused in thereportingofthis study.

Table 28. Participants With Solicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups) (Events Specific to Postvaccination) (All Participants as Treated - Second Vaccination to 42 Days Postvaccination 2) (Cohort 5 Adults and Adolescents CD4 ≥ 200, 2 Dose)

|                                           | V920   | V920   | Placebo   | Placebo   |
|-------------------------------------------|--------|--------|-----------|-----------|
|                                           | n      | (%)    | n         | (%)       |
| Participants in population with follow-up | 40     |        | 10        |           |
| withoneormoresolicitedadverseevents       | 8      | (20.0) | 2         | (20.0)    |
| withnosolicitedadverseevents              | 32     | (80.0) | 8         | (80.0)    |
| Solicitedsystemicadverseevent             | 8      | (20.0) | 2         | (20.0)    |
| Arthralgia                                | 3      | (7.5)  | 1         | (10.0)    |
| Blister                                   | 1      | (2.5)  | 0         | (0.0)     |
| Pyrexia                                   | 1      | (2.5)  | 0         | (0.0)     |
| Rash                                      | 3      | (7.5)  | 1         | (10.0)    |

Everyparticipantiscountedasingletimeforeachapplicablerowandcolumn.

Pyrexia was defined as maximum temperature ≥100.4°F(38.0°C) solicitedfrom vaccination to 42 days postvaccination.

MedDRAversion27.0wasusedin thereportingof thisstudy.

Protocol-specified events collected postvaccination ('events specific to postvaccination') included joint pain, swelling or stiffness (arthralgia/arthritis) symptoms, rash, small vesicles and/or pyrexia reported from day of vaccination until Day 42 after vaccination (after each vaccination for Cohort 5).

The proportion of participants who had ≥ 1 solicited events specific to postvaccination within 42 days after vaccination (Vaccination 1 for Cohort 5) were higher in the pooled V920 group (36.3%) compared with the pooled placebo group (22.4%) (Table 27).

Overall, the proportions of participants who had solicited events specific to postvaccination within 42 days after vaccination (Vaccination 1 for Cohort 5) were slightly higher in the 2-dose group (cohort 5 after 1 vaccination) (40%) compared to the 1-dose V920 groups (cohorts 1 to 4) (35.4%) (Table 27).

In the 2-dose V920 group (cohort 5), the proportions of participants who had solicited events specific to postvaccination within 42 days after the 1 st  vaccination (40%) was higher than after the 2 nd  vaccination (20%).

In  the  pooled  V920  group  (Cohorts  1  to  5  combined),  the  reported  solicited  events  specific  to postvaccination within 42 days after vaccination (Vaccination 1 for Cohort 5) were: arthralgia (28.9% vs.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

16.3% in placebo), pyrexia (10.4% vs. 0%, respectively), rash (6% vs. 10.2%, respectively), and blister (1.5% vs. 0, respectively) (Table 27).

In  the  pooled  V920  group  (Cohorts  1  to  5  combined),  the  frequencies  of  the  reported  solicited  events specific to postvaccination within 42 days after vaccination are, overall, slightly higher than the frequencies observed  14  days  after  vaccination:  arthralgia  (24.9%  vs.  8.2%  in  placebo),  pyrexia  (5.5%  vs.  0%, respectively), rash (4% vs. 10.2%, respectively), and blister (1% vs. 0, respectively).

In the pooled V920 group, the majority of the solicited events specific to postvaccination within 42 days after vaccination were mild (29.4%) or moderate (7.5%) in intensity. Two participants reported severe solicited AEs in the 1-dose V920 group: 2 pyrexia.

## Related events:

Table 29. Participants With Vaccine-Related Solicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups) (Events Specific to Postvaccination) (All Participants as Treated Vaccination to 42 Days Postvaccination) (Cohort 1 to Cohort 5)

|                                                      | V9201 Dose\"   | V9201 Dose\"   | V920 2 Doseb   | V920 2 Doseb   |   Po0lcdV920c | Po0lcdV920c   | Placcboc   | Placcboc   |
|------------------------------------------------------|---------------|---------------|----------------|----------------|---------------|---------------|------------|------------|
|                                                      | 11            | (%)           |                | (%)            |            11 | (%)           |            | (%)        |
| Participants in population with follow-up            | 161           |               | 40             |                |           201 |               | 49         |            |
| withoneormorevaccine-relatedsolicited adverse events | 48            | (29.8)        | 9              | (22.5)         |            57 | (28.4)        | 5          | (10.2)     |
| withnovaccine-rclated solicited adverse cvents       | 113           | (70.2)        | 31             | (77.5)         |           144 | (71.6)        | 44         | (89.8)     |
| Solicitedsystemicadverseevent                        | 48            | (29.8)        | 9              | (22.5)         |            57 | (28.4)        | 5          | (10.2)     |
| Arthralgia                                           | 30            | (18.6)        | 6              | (15.0)         |            36 | (17.9)        | 5          | (10.2)     |
| Blister                                              | 3             | (1.9)         | 0              | (0.0)          |             3 | (1.5)         | 0          | (0.0)      |
| Joint swelling                                       | 0             | (0.0)         | 0              | (0.0)          |             0 | (0.0)         | 1          | (2.0)      |
| Pyrexia                                              | 18            | (11.2)        | 3              | (7.5)          |            21 | (10.4)        | 0          | (0.0)      |
| Rash                                                 |               | (2.5)         | 2              | (5.0)          |             6 | (3.0)         | 1          | (2.0)      |

Every participantiscounted asingle time for cach applicablerow and column.

Pyrexia was defined as maximum temperature ≥100.4 °F (38.0°C) solicitedfrom vaccination to 42 days postvaccination.All cascs of pyrexia wcre dctermined by thc invcstigator tobe related.

a V920 1 Dosc=V920 1 Dose Treatment Group: Cohort 1 Adults CD4≥500 1 dosc. Cohort 2 Adults CD4&gt;350 and &lt;500 1 dose. Cohort 3 Adults CD4 ≥200 and ≤350 1 dosc. Cohort4Adolescents CD4&gt;2001 dosc.

b V920 2 Dose=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4&gt;200 2 dose. For Cohort 5, adverse events are presented for 42 days postvaccination 1. cCohorts 1-5 Adults and adolesccnts CD4&gt;200 1 or 2 dosc.For Cohort 5,adverse cvents are prescnted for 42 days postvaccination 1.

MedDRAversion 27.0 was uscd in the reporting of this study.

Most of the events specific to postvaccination within 42 days after vaccination (Vaccination 1 for Cohort 5) were assessed as related to the vaccine in the pooled V920 (28.4% out of 36.3%) and in placebo (10.2% out of 22.4%) (Table 29).

In the 2-dose V920 group (cohort 5), the proportions of participants who had related solicited events specific to postvaccination within 42 days after the 1 st  vaccination (22.5%) was slightly higher than after the 2 nd vaccination (17.5%).

In  the  pooled  V920  group  (Cohorts  1  to  5  combined),  the  reported  related  solicited  events  specific  to postvaccination within 42 days after vaccination (Vaccination 1 for Cohort 5) were: arthralgia (17.9% vs. 10.2% in placebo), pyrexia (10.4% vs. 0%, respectively), rash (3% vs. 2%, respectively), and blister (1.5% vs. 0, respectively) (Table 29).

In the pooled V920 group (Cohorts 1 to 5 combined), the frequencies of the reported related solicited events specific to postvaccination within 42 days after vaccination (table above) are slightly higher than the frequencies observed 14 days after vaccination (Table 26): arthralgia (15.9% vs. 4.1% in placebo), pyrexia (5.5% vs. 0%, respectively), rash (2% vs. 2%, respectively), and blister (1% vs. 0, respectively).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 7.2.1.3. Unsolicited Adverse Events

Table  30.  Participants  With  Unsolicited  Adverse  Events  (Incidence  &gt;  0%  in  One  or  More Vaccination  Groups)  (All  Participants  as  Treated  -  Vaccination  to  42  Days  Postvaccination) (Cohort 1 to Cohort 5)

|                                                 | V920 1 Dosea   | V920 1 Dosea   |   V920 2 Doseb | V920 2 Doseb   | Poolcd V920c   | Poolcd V920c   | Placcboc   | Placcboc   |
|-------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|------------|------------|
|                                                 | n              | (%)            |              1 | (%)            |                | (%)            |            | (%)        |
| Participants in population with follow-up       | 161            |                |             40 |                | 201            |                | 49         |            |
| with one or more unsolicited adverse events     | 87             | (54.0)         |             18 | (45.0)         | 105            | (52.2)         | 22         | (44.9)     |
| with no unsolicited adverse events              | 74             | (46.0)         |             22 | (55.0)         | 96             | (47.8)         | 27         | (55.1)     |
| Bloodandlymphaticsystemdisorders                | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Lymphadenopathy                                 | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Cardiac disorders                               | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Angina pectoris                                 | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Earandlabyrinthdisorders                        | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Cerumen impaction                               | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Eye disorders                                   | 5              | (3.1)          |              0 | (0.0)          | 5              | (2.5)          | 0          | (0.0)      |
| Conjunctivitis allergic                         | 3              | (1.9)          |              0 | (0.0)          | 3              | (1.5)          | 0          | (0.0)      |
| Eye irritation                                  | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Eye pain                                        | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Gastrointestinaldisorders                       | 18             | (11.2)         |              4 | (10.0)         | 22             | (10.9)         | 3          | (6.1)      |
| Abdominal pain                                  | 2              | (1.2)          |              1 | (2.5)          | 3              | (1.5)          | 1          | (2.0)      |
| Abdominal pain uppcr                            | 1              | (0.6)          |              1 | (2.5)          | 2              | (1.0)          | 0          | (0.0)      |
| Dental caries                                   | 3              | (1.9)          |              1 | (2.5)          | 4              | (2.0)          | 1          | (2.0)      |
| Diarrhoea                                       | 5              | (3.1)          |              0 | (0.0)          | 5              | (2.5)          | 1          | (2.0)      |
| Dyspepsia                                       | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Gastroduodenal ulccr                            | 2              | (1.2)          |              0 | (0.0)          | 2              | (1.0)          | 0          | (0.0)      |
| Gastrointestinal disorder                       | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Malpositioned tceth                             | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Oral papule                                     | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Peptic ulcer                                    | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Toothache                                       | 4              | (2.5)          |              1 | (2.5)          | 5              | (2.5)          | 0          | (0.0)      |
| Generaldisordersandadministrationsiteconditions | 15             | (9.3)          |              0 | (0.0)          | 15             | (7.5)          | 3          | (6.1)      |
| Chest pain                                      | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Fatigue                                         | 8              | (5.0)          |              0 | (0.0)          | 8              | (4.0)          | 2          | (4.1)      |
| Ill-defined disorder                            | 2              | (1.2)          |              0 | (0.0)          | 2              | (1.0)          | 0          | (0.0)      |
| Injection site induration                       | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Pain                                            | 4              | (2.5)          |              0 | (0.0)          | 4              | (2.0)          | 1          | (2.0)      |
| Tenderness                                      | 1              | (0.6)          |              0 | (0.0)          |                | (0.5)          | 0          | (0.0)      |
| Infections andinfestations                      | 50             | (31.1)         |              7 | (17.5)         | 57             | (28.4)         | 13         | (26.5)     |
| Amoebic dysentery                               | 0              | (0.0)          |              0 | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Bronchitis                                      | 5              | (3.1)          |              1 | (2.5)          | 6              | (3.0)          | 3          | (6.1)      |
| Conjunctivitis                                  | 3              | (1.9)          |              1 | (2.5)          | 4              | (2.0)          | 2          | (4.1)      |
| Conjunctivitis bacterial                        | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Cutancous leishmaniasis                         | 0              | (0.0)          |              0 | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Cystitis                                        | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Furuncle                                        | 2              | (1.2)          |              0 | (0.0)          | 2              | (1.0)          | 1          | (2.0)      |
| Gastroenteritis                                 | 2              | (1.2)          |              0 | (0.0)          | 2              | (1.0)          | 1          | (2.0)      |
| Influenza                                       | 1              | (0.6)          |              0 | (0.0)          | 1              | (0.5)          | 2          | (4.1)      |
| Malaria                                         | 11             | (6.8)          |              2 | (5.0)          | 13             | (6.5)          | 2          | (4.1)      |
| Nasopharyngitis                                 | 3              | (1.9)          |              0 | (0.0)          | 3              | (1.5)          | 1          | (2.0)      |
|                                                 | 0              | (0.0)          |              0 | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Orchitis                                        |                |                |              0 | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Otitismedia chronic Parasitic gastroenteritis   | 0 1            | (0.0) (0.6)    |              0 | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Paronychia                                      |                | (0.6)          |              0 | (0.0)          |                | (0.5)          | 0          | (0.0)      |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Pilonidal discase                                |     | (0.6)       | 0   | (0.0)       |     | (0.5)       | 0   | (0.0)       |
|--------------------------------------------------|-----|-------------|-----|-------------|-----|-------------|-----|-------------|
| Pncumonia                                        |     | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Rhinitis                                         | 9   | (5.6)       | 3   | (7.5)       | 12  | (6.0)       | 1   | (2.0)       |
| Sinobronchitis                                   | 8   | (5.0)       | 1   | (2.5)       | 9   | (4.5)       | 1   | (2.0)       |
| Tinea pedis                                      | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Tonsillitis                                      | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Tooth abscess                                    | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Tooth infcction                                  | 2   | (1.2)       | 0   | (0.0)       | 2   | (1.0)       | 0   | (0.0)       |
| Typhoid fever                                    | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Upper respiratory tract infection                | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Urinary tract infcction                          | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Vulvovaginal mycotic infection                   | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Injury,poisoningandprocedural complieations      | 3   | (1.9)       | 2   | (5.0)       | 5   | (2.5)       | 0   | (0.0)       |
| Ankle fracture                                   | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Limb injury                                      | 1   | (0.6)       | 2   | (5.0)       | 3   | (1.5)       | 0   | (0.0)       |
| Thermal burn                                     |     | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Metabolism and nutritiondisorders                | 3   | (1.9)       | 0   | (0.0)       | 3   | (1.5)       | 0   | (0.0)       |
| Decrcased appctite                               | 3   | (1.9)       | 0   | (0.0)       | 3   | (1.5)       | 0   | (0.0)       |
| Musculoskeletaland connectivetissue disorders    | 3   | (1.9)       | 1   | (2.5)       | 4   | (2.0)       | 2   | (4.1)       |
| Back pain                                        | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 1   | (2.0)       |
| Bursiltis                                        | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Myalgia                                          | 0   | (0.0)       | 0   | (0.0)       | 0   | (0.0)       | 1   | (2.0)       |
| Pain in extremity                                | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Torticollis                                      | 0   | (0.0)       | 1   | (2.5)       | 1   | (0.5)       | 0   | (0.0)       |
| Nervoussystemdisorders                           | 19  | (11.8)      | 3   | (7.5)       | 22  | (10.9)      | 3   | (6.1)       |
| Buming sensation                                 | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Caipal tunnel syndrome                           | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Cervicobrachialsyndrome                          | 0   | (0.0)       | 0   | (0.0)       | 0   | (0.0)       | 1   | (2.0)       |
| Dizziness                                        | 8   | (5.0)       | 0   | (0.0)       | 8   | (4.0)       | 1   | (2.0)       |
| Headache                                         | 7   | (4.3)       | 3   | (7.5)       | 10  | (5.0)       | 1   | (2.0)       |
| Intercostal neuralgia                            | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Paraesthesia                                     | 2   | (1.2)       | 0   | (0.0)       | 2   | (1.0)       | 0   | (0.0)       |
| Sciatica                                         | 0   | (0.0)       | 0   | (0.0)       | 0   | (0.0)       | 1   | (2.0)       |
| Psychiatric disorders                            | 3   | (1.9)       | 0   | (0.0)       | 3   | (1.5)       | 0   | (0.0)       |
| Insomnia                                         | 3   | (1.9)       | 0   | (0.0)       | 3   | (1.5)       | 0   | (0.0)       |
| Reproductivesystemandbreastdisorders Breast pain | 4   | (2.5)       | 0 0 | (0.0)       | 4   | (2.0)       | 1   | (2.0) (0.0) |
|                                                  | 1   | (0.6)       |     | (0.0) (0.0) | 1   | (0.5)       | 0   | (2.0)       |
| Dysmenorrhoca                                    | 1   | (0.6)       | 0   |             | 1   | (0.5)       | 1   |             |
| Heavy menstrual blceding                         | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Vaginal discharge                                | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
|                                                  |     |             |     |             |     |             | 3   |             |
| Bronchopncumopathy                               | 0   | (0.0)       | 0   | (0.0)       | 0   | (0.0)       | 1   | (2.0)       |
| Cough                                            | 7   | (4.3)       | 3   | (7.5)       | 10  | (5.0)       |     | (6.1)       |
| Lung disorder                                    | 2   | (1.2)       | 0   | (0.0)       | 2   | (1.0)       | 0   | (0.0)       |
| Oropharyngeal pain                               | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Skinandsubcutaneoustissuedisorders               | 9   | (5.6)       | 1   | (2.5)       | 10  | (5.0)       | 3   | (6.1)       |
| Acne                                             | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
| Ecchymosis                                       | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 0   | (0.0)       |
|                                                  | 1   |             |     |             | 1   | (0.5)       | 0   |             |
| Hyperhidrosis                                    |     | (0.6)       | 0   | (0.0)       |     |             |     | (0.0)       |
| Intertrigo Prurigo                               | 1 2 | (0.6) (1.2) | 0 0 | (0.0) (0.0) | 1 2 | (0.5) (1.0) | 0 0 | (0.0) (0.0) |
| Pruritus                                         | 4 2 | (2.5) (1.2) | 1 1 | (2.5) (2.5) | 5 3 | (2.5)       | 3   | (6.1)       |
| Vascular disorders                               |     |             |     |             |     | (1.5)       | 1   | (2.0)       |
| Diastolic hypertension                           | 1   | (0.6)       | 0   | (0.0)       | 1   | (0.5)       | 1   | (2.0)       |
| Hypertension                                     |     | (0.6)       | 1   | (2.5)       | 2   | (1.0)       | 0   | (0.0)       |

Every participant is counted a single time for cach applicable row and column.

aV9201Dosc=V9201Dose Treatment Group:Cohort 1 Adults CD4&gt;5001 dosc.Cohort 2Adults CD4&gt;350 and&lt;5001 dosc.Cohort 3 Adults CD4≥200and≤3501 dosc. Cohort 4 Adolescents CD4&gt;200 1 dosc.

b V920 2 Dose=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4&gt;200 2 dose. For Cohort 5, advcrse events are presented for 42 days postvaccination 1. c Cohorts 1-5 Adults and adolesccnts CD4&gt;2001 or 2 dosc.For Cohort 5, advcrse cvents are prcscnted for 42 days postvaccination 1.

MedDRA version 27.0 was uscd in the reporting of this study.

Approximately half of the participants in the pooled V920 (52.2%) and pooled placebo (44.9%) groups (Cohorts 1 to 5 combined) had ≥ 1 unsolicited AE within 42 days postvaccination (Vaccination 1 for Cohort 5) (Table 28). The most frequently reported unsolicited AEs were in the following SOCs: infections and infestations (28.4 % in the pooled V920 versus 26.5% in the placebo), gastrointestinal disorders (10.9% vs. 6.1%, respectively), and nervous system disorders (10.9% vs. 6.1%, respectively). The proportions of participants  who  had  unsolicited  AEs  was  generally  comparable  between  the  pooled  V920  and  pooled placebo groups.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Overall,  the  proportions  of  participants  who  had  unsolicited  events  within  42  days  after  vaccination (Vaccination 1 for Cohort 5) were slightly lower in the 2-dose group (cohort 5 after 1 vaccination) (45%) compared to the 1-dose V920 groups (cohorts 1 to 4) (54%) (Table 28).

In the 2-dose V920 group (cohort 5), the proportions of participants who had unsolicited events within 42 days after the 1 st  vaccination (45%) was slightly higher than after the 2 nd  vaccination (37.5%).

In the pooled V920 group, the majority of the unsolicited AE within the 42 days postvaccination were mild (43.3%) or moderate (10.4%) in intensity. Two participants reported severe solicited AEs in the 1-dose V920 group: 1 ankle fracture and 1 breast pain.

## Related events:

Table 31. Participants With Vaccine-Related Unsolicited Adverse Events (Incidence &gt; 0% in One or More Vaccination Groups) (All Participants as Treated -Vaccination to 42 Days Postvaccination) (Cohort 1 to Cohort 5)

|                                                         | V9201 Dosea   | V9201 Dosea   | V920 2 Doseb   | V920 2 Doseb   | Poolcd V920°   | Poolcd V920°   | Placcboc   | Placcboc   |
|---------------------------------------------------------|---------------|---------------|----------------|----------------|----------------|----------------|------------|------------|
|                                                         | 11            | (%)           |                | (%)            |                | (%)            | n          | (%)        |
| Participants in population with follow-up               | 161           |               | 40             |                | 201            |                | 49         |            |
| with one ormorevaccine-relatedunsolicitedadvcrse events | 22            | (13.7)        | 1              | (2.5)          | 23             | (11.4)         | 7          | (14.3)     |
| withnovaccine-related unsolicited adverseevents         | 139           | (86.3)        | 39             | (97.5)         | 178            | (88.6)         | 42         | (85.7)     |
| Blood and lymphaticsystem disorders                     |               | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Lymphadenopathy                                         |               | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Eye disorders                                           | 1             | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Conjunctivitis allergic                                 | 1             | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Gastrointestinal disorders                              | 1             | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 2          | (4.1)      |
| Abdominal pain                                          | 1             | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 1          | (2.0)      |
| Diarrhoca                                               | 0             | (0.0)         | 0              | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Generaldisordersandadministrationsiteconditions         | 8             | (5.0)         | 0              | (0.0)          | 8              | (4.0)          | 1          | (2.0)      |
| Fatigue                                                 | 3             | (1.9)         | 0              | (0.0)          | 3              | (1.5)          | 0          | (0.0)      |
| Ill-defined disorder                                    | 2             | (1.2)         | 0              | (0.0)          | 2              | (1.0)          | 0          | (0.0)      |
| Injection site induration                               | 1             | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Pain                                                    | 3             | (1.9)         | 0              | (0.0)          | 3              | (1.5)          |            | (2.0)      |
| Infections andinfestations                              | 0             | (0.0)         | 0              | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Influenza                                               | 0             | (0.0)         | 0              | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Musculoskeletalandconnectivetissuedisorders             | 0             | (0.0)         | 0              | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Back pain                                               | 0             | (0.0)         | 0              | (0.0)          | 0              | (0.0)          | 1          | (2.0)      |
| Nervous system disorders                                | 7             | (4.3)         | 1              | (2.5)          | 8              | (4.0)          | 1          | (2.0)      |
| Dizziness                                               | 5             | (3.1)         | 0              | (0.0)          | 5              | (2.5)          | 0          | (0.0)      |
| Headache                                                | 2             | (1.2)         | 1              | (2.5)          | 3              | (1.5)          | 1          | (2.0)      |
| Skinandsubcutaneoustissuedisorders                      | 5             | (3.1)         | 0              | (0.0)          | 5              | (2.5)          | 2          | (4.1)      |
| Hyperhidrosis                                           |               | (0.6)         | 0              | (0.0)          | 1              | (0.5)          | 0          | (0.0)      |
| Pruritus                                                | 4             | (2.5)         | 0              | (0.0)          | 4              | (2.0)          |            | (4.1)      |

Everyparticipantis counted a single time for cach applicable row and column.

*V9201Dose=V9201 DoseTreatment Group: Cohort 1 Adults CD4&gt;5001 dosc.Cohort 2Adults CD4&gt;350 and&lt;5001 dosc.Cohort 3 Adults CD4≥200 and≤3501 dosc. Cohort4AdolescentsCD4&gt;2001 dosc.

b V920 2 Dose=V920 2 Dose Treatment Group: Cohort 5 Adults and adolescents CD4&gt;200 2 dose. For Cohort 5, adverse events are presented for 42 days postvaccination 1. c Cohorts 1-5 Adults and adolesccnts CD4&gt;200 1 or 2 dosc. For Cohort 5, advcrse cvcnts are presentcd for 42 days postvaccination 1.

MedDRA version 27.0 was used in the reporting of this study.

Within 42 days postvaccination, the frequencies of the unsolicited AE assessed as related to the vaccine were 11.4% in the pooled V920 (out of 52.2%) versus 14.3% in placebo (out of 44.9%) (table above). The most frequently reported related unsolicited AEs were in the following SOCs: nervous system disorders (4% vs.  2%,  respectively)  and  the  General  disorders  and  administration  site  conditions  SOC  (4%  vs.  2%, respectively). The most frequent related unsolicited AE in the pooled V920 were: dizziness (2.5% versus 0% in placebo), pruritus (2% vs. 4.1%, respectively), headache (1.5% vs. 2%, respectively), fatigue (1.5% vs. 0%, respectively), and pain (1.5% vs. 2%, respectively).

In the 2-dose V920 group (cohort 5), the proportions of participants who had related unsolicited events within 42 days after the 1 st  vaccination was the same than after the 2 nd  vaccination (2.5%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 7.2.2. Deaths

There were no reported deaths within 1-year postvaccination.

## 7.2.3. Other Serious Adverse Events

A total of 5 SAEs were reported within 1-year postvaccination (1 year after Vaccination 1 for Cohort 5) by 3  participants  in  the  1-dose  V920  group:  hepatitis  toxic,  erysipelas,  malaria,  ankle  fracture,  and thrombophlebitis. None of the SAEs were considered related to study intervention by the investigator.

One SAE of substance-induced psychotic disorder was reported 380 days postvaccination in the 1-dose V920 group. The SAE was severe in intensity and not considered related  to study intervention by the investigator.

## 7.2.4. Discontinuations Due to Adverse Events

No participant discontinued study intervention or discontinued from the study due to an AE.

## 7.2.5. Clinical laboratory evaluations

Laboratory safety tests were collected at screening/baseline and Days 3, 7, 14, 28, 42, 56, 59, 63, 70, 84, and 98.

## 7.2.5.1. Laboratory Findings

Clinical laboratory analyses were to be performed to assess occurrence of any haematological (haemoglobin level,  WBC,  lymphocyte,  neutrophil,  eosinophil  and  platelet  count)  and  biochemical  (ALT,  AST  and creatinine) laboratory abnormality at days 0, 3, 7, 14, and 28 after each vaccination; decrease in CD4+ T cell-count ( i.e., CD4+&lt; 200 mm3); and increase in HIV viral load (i.e., VL &gt; 50 c/ml over two consecutive measurements).

No clinically meaningful changes in chemistry or haematology, including CD4 counts, were observed for the overall population (Cohorts 1 to 5 combined), pooled adults, or pooled adolescents. The majority of the laboratory findings that met predetermined criteria were mild or moderate. Few participants had laboratory findings that were severe or potentially life-threatening.

## 7.2.5.2. Viremia and Shedding of V920 Over Time

Vaccine viraemia and shedding analyses included detection of rVSV by PCR in blood, urine, and saliva in all subjects. Samples were collected at Days 3, 7, 14, 28, and 42. Participants in the 2-dose groups (V920 and placebo) also had these samples collected at Days 56, 59, 63, 70, 84, and 98. Detection of rVSV by PCR in through 42 days from skin vesicles, joint fluid, or skin biopsies was also to be analysed if specimens were obtained. It is understood specimens were not obtained as no data were submitted.

Vaccine  viraemia  and  shedding  were  assessed  using  a  qualified Quantitative  Real-time  Reverse Transcription  Polymerase  Chain  Reaction  Assay  (qRT-PCR)  comparable  to  the  one  applied  to  assess viraemia and shedding in different trials (V920-009, -012, -016 and -018).

The VSVΔG -ZEBOV Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction Assay (RTPCR) is a real-time RT-PCR assay that targets RNA sequences at the junction of the vesicular stomatitis virus (VSV) and Ebola Zaire virus (ZEBOV) GP sequences in the vector such that this assay is specific for

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

the vaccine and does not detect wild-type VSV (Indiana or New Jersey) or ZEBOV. The assay is composed of  three  principal  steps:  (1)  extraction  of  RNA  from  clinical  specimens,  (2)  parallel  amplification  and detection of vector-specific sequences at the junction of the VSV matrix gene and the inserted ZEBOV GP gene and (3) quantification of the results of the real-time RT-PCR amplification. Quantification of RT-PCR results are calculated using an external standard curve of VSVΔG -ZEBOV GP calibrators and results are reported as copies/mL.

Results are presented based on the prespecified LLOD cutoffs , which were ≥ 7.8125 copies/mL in blood, ≥ 7.8125 copies/mL in urine, and ≥ 100 copies/mL in saliva.

Viraemia  and  vaccine  shedding  were  analysed  with  counts,  percentages,  and  exact  95%  confidence intervals by vaccination group. Vaccine shedding and viremia were defined as rVSV RT-PCR ≥ LLOD or rVSV RT-PCR&gt;0. Results in terms of proportions of participants with viremia or shedding ≥ LLOD and &gt;0 are presented.

From Day 3 to Day 42 after vaccination (after Vaccination 1 for Cohort 5) in the pooled V920 group (Cohorts 1 to 5):

- The proportion of participants with detectable viremia or shedding decreased over time from Day 3 (79.6% of participants, 160/201) to Day 28 (1.5% of participants, 3/201), with no viremia or  shedding  &gt;LLOD  cutoffs  or  rVSV  RT-PCR  &gt;0  detected  at  Day  42  in  any  participants administered V920 (Table 32).
- The proportion of participants with detectable viremia decreased over time from Day 3 (79.5% of participants, 159/200) to Day 28 (1.5% of participants, 3/198), with viremia &gt;LLOD cutoff detected at Day 7 in 6/201 vaccinated subjects, and none at Days 14 and 42 (Table 33). This trend was observed in both adults and adolescents, with a higher proportion of adults (85.9%, 128/149)  with  detectable  viremia  at  Day  3  as  compared  to  adolescents  (60.8%,  31/51). Maximum level of vaccine viraemia was detected at Day 3 (2,790 copies/mL for subject 3220) and in the 3 subjects that had detectable vaccine viraemia at Day 28, maximum level was 440 copies/mL (subject 4035).
- The proportion of participants shedding in saliva to levels ≥LLOD cutoff peaked at Day 7 (16.5% of participants, 33/200) and decreased at Day 14 (10.8% of participants, 21/195) (Table 34). Vaccine shedding in saliva &gt; LLOD (100 copies/mL) was not detected at Days 28 and 42. This trend was observed in both adults and adolescents, with the proportions of participants generally comparable at each timepoint. Maximum level of vaccine shedding in saliva was detected at Day 7 (28,102 copies/mL for subject 4191). Maximum level detected at Day 3 was 13,828 (subject 4024) and maximum level detected at Day 14 was 3,223 (subject 4196).
- One participant (adult subject 3035) had shedding in urine ≥LLOD cutoff at Day 7, 76 copies/mL were detected in these participants. Vaccine shedding in urine was not detected at Days 28 and 42.

After the second vaccination in the 2-dose V920 group (Cohort 5):

- -Three participants had detectable viremia ≥LLOD cutoff (Table 32):
- o 1 participant at Day 59 (63 copies/mL detected 3 days after Vaccination 2). This adolescent participant (subject 3357) had no detectable viraemia after the 1st vaccination and had saliva shedding &gt;LLOD detected only on Day 14 (220 copies/mL).
- o 2 participants at Day 98, which correspond to 42 days after Vaccination 2. Subject 3068 (adult) had 259 copies/mL detected at visit 12, but had no detectable levels of viraemia nor shedding at any other time-point tested. Subject 3360 (adolescent) had 100 copies/mL

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

detected at visit 12 and had relatively low levels of viraemia and shedding detected after the 1st dose (25 copies/mL in plasma at Day 28 and 128 copies/mL in saliva at Day 7).

- -There was no detectable shedding ≥LLOD cutoff values in saliva or urine samples ( Table 34 ).

No participant in the pooled placebo group had detectable viremia or shedding of V920 (Table 32).

Table 32: Viremia or Shedding of Vaccine Virus (RNA Copies/mL) by Vaccination Group Over Time in Blood, Urine, or Saliva With LLOD Cutoffs (All Participants as Treated - Cohort 1 to Cohort 5)

| Time Point                                            | V920 1 Dose (N-161) Percent (m/n) [95%C1]                                                                                                                          | V9202 Dose (N-40) Percent (m/n) [95% C]]                                                                                                                                                                                                                 | Pooled V920* (102-N) ()  [95%C1]                                                                                                                                                                                                                              | Placcber (N-49) Percent (m/n) [95%C1]                                                                                                                                                                                                    |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| At any time Day 3 Day 7 Day 14 Day 42 Day 56b Day 5gh | 83.9 (135/161) [77.2%, 89.2%] 83.2 (134/161) [76.5%, 88.6%] 20.5 (33/161) [14.5%, 27.6%] 9.9(16/161) [5.8%,15.6%] 1.2(2/161) [0.2%, 4.4%] 0.0 (0/161) [0.0%, 2.3%] | 77.5 (31/40) [61.5%, 89.2%] 65.0 (26/40) [48.3%, 79.4%] 15.0(6/40) [5.7%, 29.8%] 12.8 (5/39) [4.3%, 27.4%] 2.5 (1/40) [0.1%, 13.2%] 0.0(0/40) [0.0%, 8.8%] 0.0 (0/40) [0.0%,8.8%] 2.5 (1/40) [0.1%, 13.2%] 0.0 (0/40) [0.0%,8.8%] 0.0(0/40) [0.0%, 8.8%] | 82.6 (166/201) [76.6%, 87.6%] （10/091）96 [73.4%, 84.9%] 19.4 (39/201) [14.2%, 25.6%] 10.5 (21/200) [6.6%, 15.6%] 1.5(3/201) [0.3%, 4.3%] 0.0 (0/201) [0.0%,1.8%] 0.0 (0/40) [0.0%,8,8%] 2.5 (1/40) [0.1%, 13.2%] 0.0(0/40) [0.0%,8,8%] 0.0 (0/40) [0.0%,8.8%] | 0.0(0/48) [0.0%, 7.4%] 0.0.(0/48) [0.0%, 7.4%] 0.0(0/48) [0.0%, 7.4%] 0.0(0/48) [0.0%, 7.4%] 0.0(048) [0.0%, 7.4%] 0.0 (0/48) [0.0%,7.4%] 0.0 (0/10) [0.0%,30.8%] 0.0(0/10) [0.0%, 30.8%] 0.0(0/10) [0.0%, 30.8%] 0.0(0/10) [0.0%,30.8%] |
| Day 84 Day 98*                                        |                                                                                                                                                                    | 0.0 (0/40) [0.0%, 8.8%] 5.0 (2/40) 0.6%,16.9%                                                                                                                                                                                                            | 0.0 (0/40) [0.0%,8.8%] 5.0 (2/40) [0.6%,16.9%]                                                                                                                                                                                                                | 0.0(0/10) [0.0%, 30.8%] 0.0 (0/10) 10.0%,30.8%]                                                                                                                                                                                          |

Percent=m/n and represents proportion of participants with viremia or shedding ≥7.8125 in blood, ≥7.8125 in urine, and ≥100 in saliva, where the cutoff values are the LL.ODs. Nnumber of participants with shedding or viremia data at onc or more timepoints acconding to the intcrvention to which they roccived.

n=number of participants contributing to the analysis.m=number of participants with shedding.

* V920 1 Dose=V920 1 Dose Trcatmcnt Giroup: Cohort 1 Adults CD-≥500 1 dose. Cohort 2 Adults CD4 &gt;350 and &lt;500 1 dosc. Cohort 3 Adults CD4 ≥200 and ≤350 1 dose. Cohort 4Adolescents CD4≥200 1 dose.

V920 2 Dosg=V920 2 Dos Treatment Group: Cohort 5 Adults and adolescents CD4200 2 dose.

Cohorts1-5Adults and adolescents CD4&gt;2001or2dose.

Cl=confidence interval; RNA=nbonucleic acid; LLOD-lower limit of detection.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

| Time Point                                                                                  | V9201Dose* (N=161) Percent (m/n) [95% C1]                                                                                                                       | V920 2 Doseb (N=40) Percent (m/n) [95% C1]                                                                                                                                                                                                                                         | PooledV920 (N=201) Percent (m/n) [95% C1]                                                                                                                                                                                                                                              | Placebos (N=49) Percent (m/n) [95% C1]                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Atany time Day 3 Day 7 Day 14 Day 28 Day 42 Day 56b Day 59h Day 63b Day 70b Day 84b Day 84b | 82.6 (133/161) [75.9%, 88.1%] 83.1 (133/160) [76.4%, 88.6%] 3.1 (5/161) [1.0%, 7.1%] 0.0 (0/161) [0.0%, 2.3%] 1.3 (2/158) [0.2%, 4.5%] 0.0 (0/161) [0.0%, 2.3%] | 75.0 (30/40) [58.8%, 87.3%] 65.0 (26/40) [48.3%, 79.4%] 2.5 (1/40) [0.1%, 13.2%] 0.0 (0/39) [0.0%, 9.0%] 2.5 (1/40) [0.1%, 13.2%] 0.0 (0/40) [0.0%, 8.8%] 0.0 (0/40) [0.0%, 8.8%] 2.5 (1/40) [0.1%, 13.2%] 0.0 (0/40) [0.0%, 8.8%] 0.0 (0/40) [0.0%, 8.8%] 0.0 (0/40) [0.0%, 8.8%] | 81.1 (163/201) [75.0%, 86.3%] 79.5 (159/200) [73.2%, 84.9%] 3.0 (6/201) [1.1%, 6.4%] 0.0 (0/200) [0.0%, 1.8%] 1.5 (3/198) [0.3%, 4.4%] 0.0 (0/201) [0.0%, 1.8%] 0.0 (0/40) [0.0%, 8.8%] 2.5 (1/40) [0.1%, 13.2%] 0.0 (0/40) [0.0%, 8.8%] 0.0 (0/40) [0.0%,8.8%] 0.0 (0/40) [0.0%,8.8%] | 0.0 (048) [0.0%, 7.4%] 0.0 (0/48) [0.0%, 7.4%] 0.0 (0/48) [0.0%, 7.4%] 0.0 (0/48) [0.0%, 7.4%] 0.0 (0/47) [0.0%, 7.5%] 0.0 (0/47) [0.0%, 7.5%] 0.0 (0/10) [0.0%, 30.8%] 0.0 (0/10) [0.0%,30.8%] 0.0 (0/10) [0.0%, 30.8%] 0.0 (0/10) [0.0%,30.8%] (01.0)0°0 [0.0%, 30.8%] |
| Day 98b                                                                                     |                                                                                                                                                                 | 5.0 (2/40) [0.6%, 16.9%]                                                                                                                                                                                                                                                           | 5.0 (2/40) [0.6%, 16.9%]                                                                                                                                                                                                                                                               | 0.0 (0/10) [0.0%,30.8%]                                                                                                                                                                                                                                                  |

Table 33: Viremia of Vaccine Virus (RNA Copies/mL) by Vaccination Group Over Time in Blood with LLOD Cutoff (All Participants as Treated - Cohort 1 to Cohort 5)

<!-- image -->

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Table 34: Shedding of Vaccine Virus (RNA Copies/mL) by Vaccination Group Over Time in Saliva with LLOD Cutoff (All Participants as Treated - Cohort 1 to Cohort 5)

| Time Point                                                                         | V920 1 Dose (N=161) Percent (m/n) [95%CI]                                                                                                                      | V920 2 Dose (N=40) Percent (m/n) [95% CI]                                                                                                                                                                                                               | Pooled V920c (N=201) Percent (m/n) [95%C1]                                                                                                                                                                                                                     | Placeboc (N49) Percent (m/n) [95%C]]                                                                                                                                                                                                                          |
|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Atanytime Day 3 Day 7 Day 14 Day 28 Day 42 Day 56b Day 59h Day 63b Day 70b Day 84b | 23.0 (37/161) [16.7%,30.3%] 5.0 (8/160) [2.2%, 9.6%] 17.5 (28/160) [12.0%,24.3%] 10.3 (16/156) [6.0%, 16.1%] 0.0 (0/159) [0.0%, 2.3%] 0.0 (0/159) [0.0%, 2.3%] | 22.5(9/40) [10.8%,38.5%] 2.5 (1/40) [0.1%, 13.2%] 12.5 (5/40) [4.2%, 26.8%] 12.8 (5/39) [4.3%, 27.4%] 0.0 (0/40) [0.0%,8.8%] 0.0(0/40) [0.0%,8.8%] 0.0 (0/36) [0.0%,9.7%] 0.0(0/40) [0.0%,8.8%] 0.0 (0/40) [0.0%,8.8%] 0.0(040) [0.0%, 8.8%] 0.0 (0/40) | 22.9 (46/201) [17.3%,29.3%] 4.5 (9/200) [2.1%, 8.4%] 16.5 (33/200) [11.6%,22.4%] 10.8 (21/195) [6.8%, 16.0%] 0.0 (0/199) [0.0%, 1.8%] 0.0 (0/199) [0.0%,1.8%] 0.0(0/36) [0.0%, 9.7%] 0.0(0/40) [0.0%, 8.8%] 0.0(040) [0.0%8.8%] 0.0(040) [0.0%, 8.8%] 0.0(040) | 0.0(048) [0.0%, 7.4%] 0.0 (047) [0.0%, 7.5%] 0.0(0/48) [0.0%, 7.4%] 0.0 (0/48) [0.0%, 7.4%] 0.0 (0/47) [0.0%, 7.5%] 0.0 (047) [0.0%%,7.5%] 0.0(0/9) [0.0%,33.6%] 0.0(0/10) [0.0%,30,8%] 0.0(0/10) [0.0%,30.8%] 0.0 (0/10) [0.0%,30.8%] 0.0(0/10) [0.0%,30.8%] |
| Day 84 86                                                                          |                                                                                                                                                                | [0.0%,8.8%] 0.0 (0/40) [0.0%, 8.8%]                                                                                                                                                                                                                     | [0.0%,8.8%] 0.0(040) [0.0%, 8.8%]                                                                                                                                                                                                                              | 0.0 (0/10) [0.0%, 30.8%]                                                                                                                                                                                                                                      |

## 7.2.6. Vital signs and physical findings

Vital-signs  measurements  were  collected  at  screening/baseline  and  on  Vaccination  Day  (Day  0; postvaccination); Days 3, 7, 14, 28, 42, 56, 59, 63, 70, 84, and 98; Months 6 and 12; and at study exit. Participants were prompted to report body temperatures for 42 days after vaccination starting with the day of vaccination (after each vaccination for Cohort 5).

There were no clinically meaningful findings in vital-signs measurements (blood pressure, heart rate, and respiratory rate).

In the pooled V920 group, 10.4% of participants had a maximum temperature ≥ 38.0 ° C ( ≥ 100.4 ° F) in the 42 days postvaccination (Vaccination 1 for Cohort 5) (versus 0% in placebo).

In the 2-dose V920 group (cohort 5), the proportions of participants who a maximum temperature ≥ 38.0 ° C ( ≥ 100.4 ° F) in the 42 days postvaccination after the 1 st  vaccination was higher (7.5%) than within 42 days after the 2 nd  (2.5% - 1 participant).

## 7.2.7. Safety in special groups and situations

## 7.2.7.1. Intrinsic Factors

## CD4 T-cell counts

Overall, some small non-clinically relevant differences were observed between cohort 1 and cohort 3:

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

- -Cohort 1 (CD4 ≥ 500 cells/mm3): 51 adults (41 vaccinated with V920, 10 with placebo)
- -Cohort 3 (CD4 ≥ 200 cells/mm3 and ≤ 350 cells/mm3): 50 adults (41 vaccinated with V920, 9 with placebo)

The biggest difference was observed in V920 group for the related solicited systemic AE with a frequency lower in cohort 1 (52.5% vs. 30% in placebo) than in cohort 3 (70.7% vs. 22.2% in placebo) (CSR tables 14.3-42 and 14.3-44). This was mainly driven by the reported related fatigue (cohort 1: 27.5% vs. 10% in placebo) (cohort 5: 51.2% vs. 0, respectively) and reported related headache (cohort 1: 25% vs. 20% in placebo) (cohort 5: 46.3% vs. 11.1%, respectively).

## Adults and adolescents

The frequencies of AE within the 42-days postvaccination were slightly higher in adolescents (cohorts 4 and 5) than in adults (cohorts 1 to 3 and 5) for both the V920 group (96.2% and 92.6%, respectively) and placebo group (84.6% and 72.2%) (CSR tables 14.3-9 and 14.3-10).

The  frequencies  of  solicited  AE  within  the  14  days  postvaccination  were  slightly  higher  in  adolescents (cohorts 4 and 5) than in adults (cohorts 1 to 3 and 5) for both the V920 group (92.3% and 86.6%, respectively) and placebo group (84.6% and 52.8%) (CSR tables 14.3-35 and 14.3-36). This trends was driven by the solicited local AE, and in particular, by the frequencies of injection site pain:

- -Local: V920 group (88.5% and 59.1%, respectively) and placebo group (38.5% and 25%); with injection site pain: V920 group (86.5% and 57%, respectively) and placebo group (30.8% and 22.2%)
- -Systemic: V920 group (67.3% and 77.9%, respectively) and placebo group (69.2% and 47.2%).

The  frequencies  of  related  solicited  AE  within  the  14  days  postvaccination  were  also  slightly  higher  in adolescents (cohorts 4 and 5) than in adults (cohorts 1 to 3 and 5) for both the V920 group (90.4% and 81.9%,  respectively)  and  placebo  group  (46.2%  and  38.9%)  (CSR  tables  14.3-48  and  14.3-49).  The frequencies of the related solicited local AE were identical than the frequencies of all solicited local AE (as they were all assessed as related). However, in both groups, the frequencies of the related solicited systemic AE were much lower in the adolescents versus then adults: V920 group (17.3% and 60.4%, respectively) and placebo group (7.7% and 30.6%).

The frequencies of solicited events specific to postvaccination within 42 days after vaccination were higher in adults (cohorts 1 to 3 and 5) than in adolescents (cohorts 4 and 5) for both the V920 group (41.6% and 21.2%, respectively) and placebo group (27.8% and 7.7%) (CSR tables 14.3-63 and 14.3-64). This trends was driven by the frequencies of arthralgia: V920 group (36.9% and 5.8%, respectively) and placebo group (22.2% and 0%).

The frequencies of related solicited events specific to postvaccination within 42 days after vaccination were also higher in adults (cohorts 1 to 3 and 5) than in adolescents (cohorts 4 and 5) for both the V920 group (32.2% and 17.3%, respectively) and placebo group (13.9% and 0%) (CSR tables 14.3-75 and 14.3-76). This trends was driven by the frequencies of arthralgia: V920 group (24.2% and 0%, respectively) and placebo group (13.9% and 0%).

The frequencies of unsolicited AE within the 42 days postvaccination were slightly higher in adolescents (cohorts 4 and 5) than in adults (cohorts 1 to 3 and 5) in the V920 group (65.4% and 47.7%, respectively), but not in the placebo group (38.5% and 47.2%, respectively) (CSR tables 14.3-89 and 14.3-90). This trends was driven by the frequencies of cough: V920 group (17.3% and 2%, respectively) and placebo group (15.4% and 5.6%).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The frequencies of related unsolicited AE within the 42 days postvaccination were similar in the adolescents (cohorts 4 and 5) and adults (cohorts 1 to 3 and 5) in the V920 group (11.5% and 11.4%, respectively), but not in the placebo group (23.1% and 11.1%, respectively).

## Males and females

The frequencies of AE within the 42-days postvaccination were similar in females and males for the V920 group (94% and 93.1%, respectively) (placebo group: 80% and 68.4%, respectively). Similar trend was observed for the frequencies of solicited AE within the 14 days postvaccination in the V920 group (87% and 89.1%, respectively) (placebo group: 66.7% and 52.6%, respectively) with, in the V920 group, similar frequencies of local solicited AE (64% and 69.3%, respectively) and systemic solicited AE (73% and 77.2%, respectively).

The frequencies of related solicited AE within the 14 days postvaccination were also similar in females and males for the V920 group (82% and 86.1%, respectively) (placebo group: 46.7% and 31.6%, respectively), with, in the V920 group, similar frequencies of related local solicited AE (64% and 69.3%, respectively) and related systemic solicited AE (48% and 50.5%, respectively).

The frequencies of solicited events specific to postvaccination within 42 days after vaccination were also similar in females and males for the V920 group (37% and 35.6%, respectively) (placebo group: 33.3% and 5.3%, respectively), with, in the V920 group, similar frequencies of related solicited events specific to postvaccination within 42 days after vaccination (26% and 30.7%, respectively).

The frequencies of unsolicited AE within the 42 days postvaccination were higher in females than in males in  the  V920  group  (62%  and  42.6%,  respectively)  and  in  the  placebo  group  (56.7%  and  26.3%, respectively). For example, there were an increased frequencies of malaria: V920 group (8% and 5%, respectively)  and  placebo  group  (6.7% and 0%); rhinitis: V920 group (7% and 5%, respectively) and placebo group (3.3% and 0%); and headache: V920 group (8% and 2%, respectively) and placebo group (3.3% and 0%).

The frequencies of related unsolicited AE within the 42 days postvaccination were also higher in females than in males in the V920 group (16% and 6.9%, respectively) and in the placebo group (20% and 5.3%, respectively). However, there were no clear differences per PT.

## 7.2.7.2. Extrinsic Factors

The MAH submitted analysis for the participants in Burkina Faso and Senegal (181 in total) versus the participants in Canada (20). As this number of participants in Canada is very low, analysis will not be discussed here.

## 7.2.7.3. Drug Interactions

V920  was  not  administered  concomitantly  with  any  other  vaccines  in  the  V920-015  study;  therefore, vaccine interactions were not evaluated.

## 7.2.7.4. Use in Pregnancy and Lactation

No pregnancies or lactation were reported for any participant in this study.

## 7.2.7.5. Overdose and drug abuse

There were no reports of overdose or abuse of V920 in the V920-015 study.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 7.3. Discussion

Adolescents and adults 13 to 70 years of age (inclusive) living with HIV received either 1 or 2 doses of V920 or placebo and were followed for safety through 1 year after vaccination (1 year after first vaccination for those in the 2-dose group). A total of 250 participants in Cohorts 1 to 5 (201 in the pooled V920 group, 49 in the pooled placebo group) were included in the safety population (including in the V920 group: 52 adolescents and 149 adults; 100 females and 101 males).

In the pooled V920 group (Cohorts 1 to 5 combined), the reported common injection-site adverse reactions reported within 14 days postvaccination (Vaccination 1 for Cohort 5) were injection-site pain (64.7%), swelling (5.5%), and erythema (4.5%). The reported systemic adverse reactions were headache (54.2%), fatigue  (45.3%),  feeling  hot  (25.4%),  arthralgia  (24.9%),  myalgia  (17.4%),  chills  (16.4%),  nausea (13.9%), hyperhidrosis (12.9%), abdominal pain (12.4%), diarrhoea (8.5%), pyrexia (5.5%), rash (4%), and blister (1%).

In the pooled V920 group, the frequencies of the reported solicited events specific to postvaccination within 42  days  after  vaccination  are,  overall,  slightly  higher  than  the  frequencies  observed  14  days  after vaccination: arthralgia (28.9%), pyrexia (10.4%), rash (6%), and blister (1.5%).

All these solicited AEs have been described in the SmPC section 4.8 after injection with Ervebo in healthy volunteers with similar frequencies.

The frequencies observed after 1 year postvaccination (1 year after Vaccination 1 for Cohort 5) where similar to those at 42-days postvaccination (after Vaccination 1 for Cohort 5), and no clinically meaningful unsolicited event has been reported.

Overall,  some  small  non-clinically  relevant  differences  were  observed  between  cohort  1  (CD4 ≥ 500 cells/mm3) and cohort 3 (CD4 ≥ 200 cells/mm3 and ≤ 350 cells/mm3). In particular, related fatigue and headache were more reported in cohort 3 versus cohort 1. However, the sample size of the groups were too small to make definitive conclusion (per group: around 40 vaccinated with V920 and 10 with placebo).

Therefore, in this study 015, the safety profile of the V920 vaccine in 52 adolescents and 149 adults living with HIV on antiretroviral therapy with a CD4+ T-lymphocyte count greater than or equal to 200 cells/mm3 was generally consistent with the known safety profile of Ervebo.

Safety analyses were additionally presented by subgroup by age category (adults or adolescents) and sex (males or females). Overall, no clinically meaningful differences in AE profiles were observed. However, the results should be interpreted with caution due to the small sample sizes in the subgroups (52 adolescents and 149 adults; 100 females and 101 males).

Concerning vaccine viraemia and shedding in saliva and urine post-vaccination, a qualified Quantitative Real-time  Reverse  Transcription  Polymerase  Chain  Reaction  Assay  (qRT-PCR)  was  applied  that  is comparable to the one applied to assess viraemia and shedding in previous V920 clinical studies, such as V920-016 PREVAC trial. Results in terms of proportions of participants with viremia or shedding at different time-point post-vaccination were submitted. As compared to already available data concerning proportions of  subject  with  positive  vaccine  viraemia  or  shedding  in  saliva  after  ERVEBO  vaccination,  no  major differences were noted in that respect in participants of V920-015. The MAH also submitted quantitative data and individual trajectories of copies/mL over time. Collectively, viraemia and shedding results from V920-015 do not indicate notable differences as compared to previous clinical trials in terms of proportion of positive subjects, kinetics of vaccine viraemia and shedding, quantitative data in adolescents and adults 13 to 70 years of age (inclusive) living with HIV.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## 8. Risk management plan

The MAH submitted an updated RMP version with this application. The (main) proposed RMP changes were the following:

- Include study data following the completion of V920-015, to remove V920-015 as an additional pharmacovigilance (PV) activity, and to remove 'Exposure in HIV-Infected Individuals' as Missing Information.
- Include data from Expanded Access Protocol 5 (EAP5) and to remove EAP5 as an additional PV activity.

The significant changes in this RMP encompass updated epidemiology information, incorporation of clinical trial data from study V920-015 throughout the document, inclusion of Expanded Access Protocol 5 (EAP5) data, and the removal of V920-015 and EAP5 as additional PV activities in Part V. 'Exposure in HIVInfected Individuals' has been removed from the list of Missing Information.

## Summary of the safety concerns

## Table SVIII.1: Summary of Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                      |
|------------------------------|-------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                            |
| Important potential risks    | • Viral shedding/secondary transmission to close contacts, particularly immunocompromised hosts |
| Missing information          | • Exposure during pregnancy • Exposure during lactation • Exposure in HIV-infected individuals  |

The following information regarding exposure in Expanded Access Protocol 005 [EAP5] was added in Table SIV 3.1 Exposure of Special Populations Included or not in Clinical Trial Development Programs :

'Patients with HIV and/or AIDS

…

A total of 201 adolescents and adults living with HIV (CD4 T-Cell counts ≥ 200 cells/mm3 on antiretroviral therapy with an undetectable viral load [&lt;40 copies/mL]) were vaccinated with rVSV Δ G-ZEBOV-GP in V920-015.'

'Pregnant or breastfeeding women

…

The rVSVΔG -ZEBOV-GP vaccine was administered in the context of Expanded Access Protocol 005 ([hereafter referred to as EAP5] Compassionate ring vaccination study sponsored by the DRC Ministry of Public Health, WHO, and MSF to evaluate the safety of the Ebola vaccine in the DRC) from AUG-2018 through JUN-2020 in an outbreak setting and during a complex humanitarian situation. In JUN-2019, the protocol was amended so that pregnant individuals after the first trimester and lactating individuals were eligible for inclusion and vaccination.

A total of 1882 vaccinees were reported to be pregnant or lactating at time of vaccination; 22 of 1882 pregnant or lactating vaccinees were reported to develop EVD, and there is no further information

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

regarding lactating vaccinees. No safety information was provided regarding lactating vaccinees.

Pregnancy outcomes were available for 1509 vaccinated pregnant individuals; the majority were ≤35 years of age and were reported to be in either the second or third trimester of pregnancy. Other reported obstetric history was limited, and few individuals had a reported history of abortion, c-section, and hypertension.

The majority of individuals reported full-term deliveries [Ref. 5.4: 08RBCR]. A small number of participants reported abortions and stillbirths. Three of these pregnant vaccinees developed EVD, none of whom died. Two maternal deaths unrelated to EVD were reported and neither were considered related to vaccination by the investigator. Seven full-term and 1 pre-term perinatal deaths were reported. There are limitations to the completeness of the data collection given the challenging outbreak setting in which EAP5 was conducted.

…'

## PRAC Rapporteur assessment comment:

The removal of the area of Missing information 'Exposure in HIV-Infected Individuals' [and all related RMP parts] is consequential to the finalisation of the category 3 PASS V920-015 - see assessment of study data above - and is accepted.

The updates related to Part II Modules SI Epidemiology , SIII Clinical trial exposure , SIV Populations not studied in clinical trials [including exposure in EAP5], SV Post-authorisation experience are administrative, and accepted.

No further changes in the RMP summary of safety concerns are being proposed. This is accepted.

## 8.1. Overall conclusion on the RMP

The changes to the RMP are acceptable. RMP version 3.0 is acceptable.

## 9. Changes to the Product Information

As a result of this variation, sections 4.4., 4.8, and 5.1 of the SmPC are being updated to include safety and immunogenicity data following the results from study V920-015.

In addition, the list of local representatives in the PL is being removed.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 10. Request for supplementary information

## 10.1. Major objections

None.

## 10.2. Other concerns

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Clinical aspects

1. Applied assay methods to assess humoral immune responses (GP-ELISA and PRNT) and to assess viraemia and shedding and laboratories where assays were performed need to be confirmed. Detailed descriptions of the applied assays and of their status are expected if not yet submitted. Whether samples collected from participants from African sites were gamma-irradiated or not should be clarified.
2. In study V920-015, 3 different V920 Drug Product Lots were used, all had a potency ≥ 2 x 10E7 pfu/mL. Actual potency of the 3 lots and distribution by cohort/country were not provided and should be submitted for completeness.
3. An unexpected trend of an increase in GP-ELISA GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the combined 1-dose cohorts is noted (also reflected in terms of GP-ELISA GMFIs results). Similarly, a trend towards an increase in PRNT GMT at Month 12 as compared to Day 28 GMT after 1 dose of V920 is noted (also reflected in terms of PRNT GMFIs results). The MAH should clarify and further discuss these unexpected trends also by taking into consideration the data presented by cohort, and separately for participants from African and Canadian clinical sites.
4. Quantitative viremia and shedding data and individual trajectories of copies/mL over time should be submitted.

## RMP aspects

None.

## 11. Assessment of the responses to the request for supplementary information

## 11.1. Major objections

Not applicable.

## 11.2. Other concerns

## Clinical aspects

## Question 1

Applied assay methods to assess humoral immune responses (GP-ELISA and PRNT) and to assess viraemia and shedding and laboratories where assays were performed need to be confirmed. Detailed descriptions of the applied assays and of their status are expected if not yet submitted. Whether samples collected from participants from African sites were gamma-irradiated or not should be clarified.

## Summary of the MAH's response

The MAH specified that immunogenicity results reported for V920-015 were generated from a validated proprietary glycoprotein enzyme-linked immunosorbent assay GP-ELISA, and a validated plaque reduction neutralization test (PRNT).

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The MAH clarified that samples collected from participants from African sites were not gamma-irradiated.

The MAH clarified that viraemia and shedding results reported for V920-015 were generated from a qualified Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) assay.

All assays were performed at Q2 Solutions/IQVIA Laboratories at 2 locations in the US and have been used in V920 Protocols -009, -012, -016 and -018.

The MAH provided brief assay descriptions that have been included in the corresponding sections when needed.

## Assessment of the MAH's response

The MAH did not submit detailed descriptions of the applied assays as requested but provided brief assay descriptions. However this is deemed acceptable, considering that the MAH clarified that the applied assays have been used in V920 Protocols -009, -012, -016 and -018 and hence were already assessed in different procedures.

The MAH clarified that samples collected from participants from African sites were not gamma-irradiated.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

## Question 2

In study V920-015, 3 different V920 Drug Product Lots were used, all had a potency ≥ 2 x 10E7 pfu/mL. Actual potency of the 3 lots and distribution by cohort/country were not provided and should be submitted for completeness.

## Summary of the MAH's response

The MAH provided V920 drug lot numbers, actual potencies, and specified to which country each lot was shipped (Table below)

| Lot Number                                          | Potency'                                 | Country Vaccine Shipped To               |
|-----------------------------------------------------|------------------------------------------|------------------------------------------|
| WL00067464 (underlying drug product lot WL00063635) | 1.3 x 10* pfu/mL                         | Burkina Faso, Senegal                    |
| 0000852249 (underlying drug product lot WL00067929) | 3.0 x 10* pfu/mL                         | Burkina Faso, Senegal, Canada            |
| WL00061392 (underlying diug product lot WL00061283) | 5.4 x 107 pfu/mL                         | Canada                                   |
| 1 Per Certificate of Analysis at release            | 1 Per Certificate of Analysis at release | 1 Per Certificate of Analysis at release |

Data on distribution of the different lots by cohort/country are not compiled and were therefore not submitted.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

## Assessment of the MAH's response

The MAH submitted the requested information on the 3 different V920 Drug Product Lots applied (V920 drug lot numbers, actual potencies, and to which country each lot was shipped). Data on distribution of the different lots by cohort/country are not available (not compiled) and were therefore not submitted. This is a limitation given the differences in potency of the different lots, ranging from 5.4 x 10E7 pfu/mL to 3.0 x 10E8 pfu/mL.

## Conclusion

- [x] Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

## Question 3

An unexpected trend of an increase in GP-ELISA GMTs at Month 6 and Month 12 as compared to Day 28 GMT in the combined 1-dose cohorts is noted (also reflected in terms of GP-ELISA GMFIs results). Similarly, a trend towards an increase in PRNT GMT at Month 12 as compared to Day 28 GMT after 1 dose of V920 is noted (also reflected in terms of PRNT GMFIs results). The MAH should clarify and further discuss these unexpected trends also by taking into consideration the data presented by cohort, and separately for participants from African and Canadian clinical sites.

## Summary of the MAH's response

The MAH specified in their answer that the overall kinetics of the GP-ELISA and PRNT responses are consistent with previously reported V920 clinical studies and with nonhuman primate data when tested in the same validated assays.

Suggestion of a trend of increase in GP-ELISA and PRNT responses after Day 28 has been observed in both human and NHP studies; it has been observed more frequently in PRNT responses. In clinical studies, these findings have been observed in children and adults, including adults &gt;50 years of age and in trial participants in both African and ex-African countries. Although this study was not powered to make direct comparisons among different time points or by subgroup, these findings are biologically plausible and may be associated with maturation of the immune response. Thus, the observed increase in antibody titers at later time points may be explained by the natural maturation and evolution of the immune response following vaccination. This process can result in a gradual increase or sustained elevation of antibody titers months after vaccination, even in the absence of additional antigen exposure.

In support of their hypothesis to explain the observed unexpected trends, the MAH referred to two publications related to germinal centres (Mesin et al.; Immunity. 2016 Sep 20;45:471-82 and Victora et al.; Annu Rev Immunol. 2012;30:429-57.

Finally, the MAH specified that the validated assays are conducted with appropriate controls to monitor expected performance across assay runs and the trends are consistent across participants and studies regardless of the assay run.

## Assessment of the MAH's response

The MAH speculated that the unexpected trends in antibody responses might be associated with maturation of the immune response, which can result in a gradual increase or sustained elevation of antibody titers months after vaccination, even in the absence of additional antigen exposure.

It is agreed with the MAH, that these unexpected trends were also notable in other clinical studies and were also discussed at the time of EoI to include infants &gt;1 YoA in the indication. Nevertheless, these unexpected trends appear more pronounced in study V920-015 and the MAH did not discuss if differences in CD4+ T cell counts in the different cohorts or differences in recruitment country might have had an impact on this aspect.

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

The MAH specified that these unexpected trends in kinetic of antibody responses cannot be attributed to the applied ELISA and PRNT assays, this is acknowledged.

## Conclusion

Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

## Question 4

Quantitative viraemia and shedding data and individual trajectories of copies/mL over time should be submitted.

## Summary of the MAH's response

The MAH submitted figures representing quantitative viraemia and shedding data over time (Figures below) and individual vaccine viraemia and shedding listings.

Figure1 ViremiaofVaccineVirusbyVaccinationGroupOverTimeinPlasma (All Participants as Treated) (Cohort 1 to Cohort 5)

<!-- image -->

Day

Figure 2 Shedding of VaccineVirus byVaccination Group Over Time inSaliva (AllParticipantsas Treated) (Cohort 1 to Cohort 5)

<!-- image -->

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

<div style=\"page-break-after: always\"></div>

Figure 3 SheddingofVaccineVirusbyVaccinationGroupOverTimeinUrine (AllParticipantsasTreated) (Cohort1toCohort5)

<!-- image -->

## Assessment of the MAH's response

The MAH submitted the requested quantitative viraemia and shedding data and individual trajectories of copies/mL over time.

These overall do not indicate major differences in terms of vaccine viraemia nor saliva/urine shedding in the adolescent and adult participants (13-70 YoA) living with HIV of study V920-015 as compared to data already available and assessed in different procedures (marketing authorisation, extension of indication).

Based on the submitted results, proposed amendment to the SmPC concerning shedding are deemed acceptable.

## Conclusion

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

- [x] Overall conclusion and impact on benefit-risk balance has/have been updated accordingly

- [ ] No need to update overall conclusion and impact on benefit-risk balance

Type II variation assessment report EMADOC-1700519818-2258789